Stephane Marie Oudard
#118,620
Most Influential Person Now
Stephane Marie Oudard's AcademicInfluence.com Rankings
Stephane Marie Oudardmedical Degrees
Medical
#1750
World Rank
#2122
Historical Rank
Urology
#8
World Rank
#9
Historical Rank
Oncology
#89
World Rank
#93
Historical Rank
Stephane Marie Oudardphilosophy Degrees
Philosophy
#5283
World Rank
#8043
Historical Rank
Logic
#2588
World Rank
#3600
Historical Rank
Download Badge
Medical Philosophy
Stephane Marie Oudard's Degrees
- Doctorate Medicine Université Paris Cité
- PhD Urology Université Paris Cité
Why Is Stephane Marie Oudard Influential?
(Suggest an Edit or Addition)Stephane Marie Oudard's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. (2004) (5412)
- Sorafenib in advanced clear-cell renal-cell carcinoma. (2007) (4691)
- Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. (2007) (4385)
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial (2010) (2927)
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial (2008) (2856)
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma (2009) (2096)
- Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. (2009) (1081)
- Phase 3 trial of everolimus for metastatic renal cell carcinoma (2010) (968)
- Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial (2018) (961)
- Apalutamide Treatment and Metastasis‐free Survival in Prostate Cancer (2018) (824)
- Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. (2013) (636)
- Sunitinib Alone or after Nephrectomy in Metastatic Renal‐Cell Carcinoma (2018) (585)
- Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. (2009) (578)
- PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. (2013) (547)
- Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. (2013) (541)
- Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. (2019) (473)
- Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management (2007) (374)
- Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial. (2016) (338)
- Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal (2018) (333)
- Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer (2015) (320)
- Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. (2008) (313)
- Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. (2011) (296)
- Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy (2011) (296)
- Characteristics and Clinical Impacts of the Immune Environments in Colorectal and Renal Cell Carcinoma Lung Metastases: Influence of Tumor Origin (2013) (280)
- Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. (2008) (237)
- Mutations in OGG1, a gene involved in the repair of oxidative DNA damage, are found in human lung and kidney tumours (1998) (234)
- Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting (2015) (223)
- Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. (2021) (222)
- Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA. (2017) (218)
- Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer (2017) (213)
- Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. (2013) (207)
- Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. (2013) (197)
- Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma (2017) (194)
- Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. (2009) (193)
- A Decrease of Regulatory T Cells Correlates With Overall Survival After Sunitinib-based Antiangiogenic Therapy in Metastatic Renal Cancer Patients (2010) (193)
- Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. (2014) (192)
- Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. (2015) (190)
- Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1. (2016) (187)
- Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients (2009) (186)
- ctDNA guiding adjuvant immunotherapy in urothelial carcinoma (2021) (179)
- Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales) study. (2007) (173)
- Home blood-pressure monitoring in patients receiving sunitinib. (2008) (171)
- Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. (2012) (169)
- Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. (2021) (164)
- Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. (2005) (163)
- Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. (2018) (161)
- Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma (2015) (160)
- Management of Prostate Cancer in Elderly Patients: Recommendations of a Task Force of the International Society of Geriatric Oncology. (2017) (155)
- BONE HEALTH IN CANCER: ESMO CLINICAL PRACTICE GUIDELINES. (2020) (153)
- Sequential sorafenib and sunitinib for renal cell carcinoma. (2009) (152)
- Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. (2014) (151)
- IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial. (2016) (150)
- Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel. (2014) (147)
- Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. (2013) (145)
- Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial (2013) (144)
- Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. (2005) (141)
- Tim-3 Expression on Tumor-Infiltrating PD-1+CD8+ T Cells Correlates with Poor Clinical Outcome in Renal Cell Carcinoma. (2017) (141)
- Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. (2021) (139)
- Sorafenib for Older Patients With Renal Cell Carcinoma: Subset Analysis From a Randomized Trial (2008) (138)
- Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-{alpha}) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC) (2006) (135)
- Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT. (2010) (135)
- Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. (2020) (134)
- Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. (2021) (133)
- Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. (2011) (130)
- Sunitinib in metastatic renal cell carcinoma patients with brain metastases (2011) (128)
- Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer. (2009) (124)
- Apalutamide and Overall Survival in Prostate Cancer. (2020) (124)
- Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. (2012) (123)
- Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer. (2015) (118)
- Phase II Study of Lonidamine and Diazepam in the Treatment of Recurrent Glioblastoma Multiforme (2003) (116)
- Tumor Cells Hijack Macrophage-Produced Complement C1q to Promote Tumor Growth (2019) (115)
- High glycolysis in gliomas despite low hexokinase transcription and activity correlated to chromosome 10 loss. (1996) (114)
- Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. (2015) (114)
- Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2. (2015) (114)
- Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer (2012) (112)
- Platelet microparticles: a potential predictive factor of survival in hormone-refractory prostate cancer patients treated with docetaxel-based chemotherapy. (2009) (109)
- Alterations of the DNA repair gene OGG1 in human clear cell carcinomas of the kidney. (2000) (106)
- Gliomas are driven by glycolysis: putative roles of hexokinase, oxidative phosphorylation and mitochondrial ultrastructure. (1997) (103)
- Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model. (2015) (102)
- Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial. (2011) (101)
- Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials. (2010) (101)
- Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial. (2018) (100)
- Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results of a multinational phase III trial (TROPIC). (2010) (98)
- Docetaxel reintroduction in patients with metastatic castration‐resistant docetaxel‐sensitive prostate cancer: a retrospective multicentre study (2010) (97)
- The Peripheral Benzodiazepine Receptors: A Review (2004) (97)
- Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. (2018) (97)
- TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer. (2011) (96)
- A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings (2011) (96)
- Transcription factor E3 and transcription factor EB renal cell carcinomas: clinical features, biological behavior and prognostic factors. (2011) (94)
- Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib (2013) (94)
- Light-induced photoactivation of hypericin affects the energy metabolism of human glioma cells by inhibiting hexokinase bound to mitochondria. (1998) (93)
- Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. (2022) (93)
- Prognostic factors of renal cell carcinoma. (2003) (88)
- Antiangiogenic therapy for advanced renal cell carcinoma: Management of treatment-related toxicities (2012) (87)
- Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients. (2019) (87)
- Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study. (2019) (85)
- Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib. (2010) (84)
- Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). (2006) (83)
- Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer. (2004) (83)
- Matched case‐control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel‐induced onycholysis and cutaneous toxicity of the foot (2008) (80)
- Immune‐related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors (2017) (79)
- Sequential use of sorafenib and sunitinib in renal cancer: Retrospective analysis in 90 patients (2007) (79)
- Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer Centers. (2002) (79)
- Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma. (2016) (79)
- Collecting duct carcinoma of the kidney: a clinicopathological study of 9 cases. (2003) (76)
- Complete cerebral response with sunitinib for metastatic renal cell carcinoma. (2007) (75)
- Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA) (2018) (74)
- First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)†. (2015) (72)
- Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib (2008) (72)
- Prognostic impact of baseline serum C‐reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib (2014) (71)
- Intracellular pH governs the subcellular distribution of hexokinase in a glioma cell line. (1996) (71)
- Metastatic Renal Cell Carcinoma: Relationship Between Initial Metastasis Hypoxia, Change After 1 Month's Sunitinib, and Therapeutic Response: An 18F-Fluoromisonidazole PET/CT Study (2011) (70)
- Treatment options in renal cell carcinoma: past, present and future. (2007) (70)
- Progress in emerging therapies for advanced prostate cancer. (2013) (70)
- Sunitinib in metastatic renal cell carcinoma (mRCC): Preliminary assessment of toxicity in an expanded access trial with subpopulation analysis (2007) (68)
- RAD001 vs placebo in patients with metastatic renal cell carcinoma (RCC)after progression on VEGFr-TKI therapy: Results from a randomized, double-blind, multicenter Phase-III study (2008) (66)
- Patients' self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15). (2014) (66)
- Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients. (2007) (64)
- A phase II trial of sunitinib in patients with renal cell cancer and untreated brain metastases. (2014) (63)
- Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941. (2007) (59)
- Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit. (2012) (59)
- LBA23 Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361 (2020) (57)
- Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial. (2013) (57)
- Randomized, placebo-controlled, phase III trial of sunitinib in combination with prednisone (SU+P) versus prednisone (P) alone in men with progressive metastatic castration-resistant prostate cancer (mCRPC). (2011) (57)
- Targeting Resident Memory T Cells for Cancer Immunotherapy (2018) (56)
- Cabazitaxel vs docetaxel in chemotherapy-naive (CN) patients with metastatic castration-resistant prostate cancer (mCRPC): A three-arm phase III study (FIRSTANA). (2016) (56)
- A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial. (2012) (55)
- Mitochondria‐bound hexokinase as target for therapy of malignant gliomas (1995) (55)
- Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile? (2008) (55)
- Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts. (2003) (54)
- [Vascular and renal effects of anti-angiogenic therapy]. (2008) (53)
- Sunitinib for the treatment of metastatic renal cell carcinoma. (2011) (53)
- Optimal cut-off for neutrophil-to-lymphocyte ratio: Fact or Fantasy? A prospective cohort study in metastatic cancer patients (2018) (52)
- Effi cacy of everolimus in advanced renal cell carcinoma : a double-blind , randomised , placebo-controlled phase III trial (2008) (52)
- A multicenter phase III comparison of docetaxel (D) + prednisone (P) and mitoxantrone (MTZ) + P in patients with hormone-refractory prostate cancer (HRPC). (2004) (51)
- Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. (2012) (51)
- Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors (2016) (50)
- Clinical and experimental progression of a new model of human prostate cancer and therapeutic approach. (2001) (50)
- Triple combination of bevacizumab, gemcitabine and platinum salt in metastatic collecting duct carcinoma. (2013) (49)
- Effective chemotherapy for hormone-refractory prostate cancer (HRPC): present status and perspectives with taxane-based treatments. (2007) (48)
- Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative Group. (2003) (48)
- Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC) (2015) (48)
- Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial. (2017) (48)
- Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer. (2014) (48)
- Androgen deprivation therapy (ADT) plus docetaxel (D) versus ADT alone for hormone-naïve metastatic prostate cancer (PCa): Long-term analysis of the GETUG-AFU 15 phase III trial. (2015) (48)
- Cytoreductive nephrectomy (CN) in metastatic renal cancer (mRCC): Update on Carmena trial with focus on intermediate IMDC-risk population. (2019) (47)
- Pro-angiogenic gene expression is associated with better outcome on sunitinib in metastatic clear-cell renal cell carcinoma (2017) (47)
- Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues (2010) (47)
- Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer (2019) (47)
- Potentiation of lonidamine and diazepam, two agents acting on mitochondria, in human glioblastoma treatment. (1998) (46)
- Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): Impact of crossover on survival. (2007) (46)
- Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer. (2019) (46)
- Docetaxel rechallenge after an initial good response in patients with metastatic castration‐resistant prostate cancer (2015) (46)
- Comprehensive Analysis of HLA-DR- and HLA-DP4-Restricted CD4+ T Cell Response Specific for the Tumor-Shared Antigen Survivin in Healthy Donors and Cancer Patients1 (2008) (46)
- VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib – a multicentric retrospective analysis (2014) (45)
- Final analysis of COMET-1: Cabozantinib (Cabo) versus prednisone (Pred) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E). (2015) (45)
- Expression of genes involved in chemoresistance, proliferation and apoptosis in clinical samples of renal cell carcinoma and correlation with clinical outcome. (2002) (45)
- The medical management of prostate cancer: a multidisciplinary team approach (2007) (45)
- Phase II study of vinorelbine in patients with androgen-independent prostate cancer. (2001) (44)
- Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. (2022) (44)
- Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): Impact of crossover on survival (2006) (44)
- Phase I/II dose-finding, safety and efficacy study of radium-223 dichloride in renal cell carcinoma patients with bone metastases (2016) (44)
- Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets (2010) (44)
- Renal insufficiency and anticancer drugs in elderly cancer patients: a subgroup analysis of the IRMA study. (2009) (43)
- Final survival results from SPARTAN, a phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC). (2020) (43)
- Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders (2018) (43)
- IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC). (2020) (42)
- Lung Cancer and Renal Insufficiency: Prevalence and Anticancer Drug Issues (2008) (42)
- Prognostic significance of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma treated with first-line sunitinib: a European multiinstitutional study. (2014) (42)
- Sunitinib Alone or After Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Is There Still a Role for Cytoreductive Nephrectomy? (2021) (41)
- First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG). (2015) (41)
- Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma (2009) (41)
- Trastuzumab (Herceptin) in metastatic transitional cell carcinoma of the urinary tract: report on six patients. (2005) (40)
- Short- and long-term safety with sunitinib in an expanded access trial in metastatic renal cell carcinoma (mRCC) (2008) (40)
- Current and emerging treatment modalities for metastatic castration‐resistant prostate cancer (2011) (40)
- First-line sunitinib in type I and II papillary renal cell carcinoma (PRCC): SUPAP, a phase II study of the French Genito-Urinary Group (GETUG) and the Group of Early Phase trials (GEP). (2012) (40)
- Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy (ELM-PC 5 Trial). (2014) (39)
- The use of estramustine phosphate in the modern management of advanced prostate cancer (2011) (39)
- Sensitization of multidrug-resistant colon cancer cells to doxorubicin encapsulated in liposomes (2004) (38)
- Prostate‐specific antigen kinetics in localized and advanced prostate cancer (2009) (38)
- Outcomes in elderly patients admitted to the intensive care unit with solid tumors (2017) (36)
- Phase I Safety and Pharmacodynamic of Inecalcitol, a Novel VDR Agonist with Docetaxel in Metastatic Castration-Resistant Prostate Cancer Patients (2014) (36)
- Optimisation of the tumour response threshold in patients treated with everolimus for metastatic renal cell carcinoma: analysis of response and progression-free survival in the RECORD-1 study. (2012) (35)
- Tumor Microenvironment Features as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors (ICI) in Metastatic Clear Cell Renal Cell Carcinoma (mccRCC) (2021) (34)
- A practical approach to improve safety and management in chemotherapy units based on the PROCHE - programme for optimisation of the chemotherapy network monitoring program. (2013) (34)
- Phase II trial evaluating a docetaxel‐capecitabine combination as treatment for hormone‐refractory prostate cancer (2006) (34)
- What is the real impact of bone pain on survival in patients with metastatic hormone‐refractory prostate cancer treated with docetaxel? (2009) (33)
- Atezolizumab (atezo) vs. chemotherapy (chemo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Immune biomarkers, tumor mutational burden (TMB), and clinical outcomes from the phase III IMvigor211 study. (2018) (33)
- Sunitinib in patients with or without prior nephrectomy (Nx) in an expanded access trial of metastatic renal cell carcinoma (mRCC) (2008) (33)
- French Intensive Care Society, International congress – Réanimation 2016 (2016) (33)
- Response of renal cell carcinoma pancreatic metastasis to sunitinib treatment: a retrospective analysis. (2007) (32)
- KEYNOTE-365 cohort A updated results: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). (2020) (32)
- Genitourinary tumors, non-prostate (2012) (31)
- Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors. (2019) (31)
- Meta-Analysis of Randomised Trials Comparing Gemcitabine-Based Doublets versus Gemcitabine Alone in Patients with Advanced and Metastatic Pancreatic Cancer (2007) (31)
- Gemcitabine or gemcitabine plus oxaliplatin in the first-line treatment of patients with advanced transitional cell carcinoma of the urothelium unfit for cisplatin-based chemotherapy: a randomized phase 2 study of the French Genitourinary Tumor Group (GETUG V01). (2011) (31)
- [Chemotherapy: principles and practice]. (2002) (30)
- Radiological evaluation of response to treatment: application to metastatic renal cancers receiving anti-angiogenic treatment. (2014) (30)
- Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma (2015) (29)
- RANDOMISED PHASE III TRIAL OF THE MULTIKINASE INHIBITOR SORAFENIB (BAY 43-9006) IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (RCC) (2006) (29)
- Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma-Results of the REchallenge with SUnitinib in MEtastatic RCC (RESUME) Study. (2016) (29)
- Phase II study of the oral HIF-2α inhibitor MK-6482 for Von Hippel-Lindau disease–associated renal cell carcinoma. (2020) (29)
- Phase III AXIS trial for second-line metastatic renal cell carcinoma (mRCC): Effect of prior first-line treatment duration and axitinib dose titration on axitinib efficacy. (2012) (29)
- Therapeutic Strategy for Treatment of Metastatic Non-Small Cell Lung Cancer (2008) (28)
- Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib (2014) (28)
- Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms (2007) (28)
- BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer. (2020) (28)
- Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer ( mCRPC ) with or without neuroendocrine differentiation : results of the French GenitoUrinary Tumor Group ( GETUG ) P 01 trial (2011) (27)
- Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration (2013) (27)
- LBA25 Results from the phase II biomarker driven trial with nivolumab (N) and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer (m-ccRCC) patients (pts): The BIONIKK trial (2020) (27)
- Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab (2020) (27)
- Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation (2015) (26)
- First-line antiangiogenics for metastatic renal cell carcinoma: A systematic review and network meta-analysis. (2016) (26)
- Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access Program. (2020) (26)
- Optimal management of metastatic renal cell carcinoma: an algorithm for treatment (2009) (26)
- Sunitinib in kidney cancer: 10 years of experience and development (2017) (26)
- Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy (2017) (25)
- Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study. (2020) (25)
- Prediction of Everolimus Toxicity and Prognostic Value of Skeletal Muscle Index in Patients With Metastatic Renal Cell Carcinoma (2017) (25)
- Randomized Study of Intravenous versus Subcutaneous Interleukin-2, and IFNα in Patients with Good Prognosis Metastatic Renal Cancer (2008) (25)
- Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma. (2015) (25)
- 17LBA Results from an open-label, randomized, controlled Phase 3 study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic RCC (2015) (25)
- Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial. (2022) (25)
- A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors (2019) (24)
- Treatment outcome for metastatic papillary and chromophobe renal cell carcinoma (RCC) patients treated with tyrosine-kinase inhibitors (TKIs) sunitinib and sorafenib (2007) (24)
- Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database. (2018) (24)
- Validation of VEGFR1 rs9582036 as predictive biomarker in metastatic clear‐cell renal cell carcinoma patients treated with sunitinib (2016) (24)
- Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies. (2016) (24)
- Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France (2015) (24)
- An ambispective observational study in the safety and efficacy of abiraterone acetate in the French temporary authorizations for use (ATU): Predictive parameters of response. (2012) (24)
- Effect of 1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinoline carboxamide (PK11195), a specific ligand of the peripheral benzodiazepine receptor, on the lipid fluidity of mitochondria in human glioma cells. (1999) (24)
- Low immunogenicity of seasonal trivalent influenza vaccine among patients receiving docetaxel for a solid tumour: results of a prospective pilot study (2011) (23)
- Final analysis of the CheckMate 025 trial comparing nivolumab (NIVO) versus everolimus (EVE) with >5 years of follow-up in patients with advanced renal cell carcinoma (aRCC). (2020) (23)
- RANK/OPG ratio of expression in primary clear-cell renal cell carcinoma is associated with bone metastasis and prognosis in patients treated with anti-VEGFR-TKIs (2015) (23)
- Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial (2019) (23)
- Prognostic factors of survival in patients with metastatic castration resistant prostate cancer (mCRPC) treated with cabazitaxel: Sequencing might matter. (2013) (23)
- Duration of response to androgen-deprivation therapy (ADT) and efficacy of secondary hormone therapy, docetaxel (D), and cabazitaxel (C) in metastatic castration-resistant prostate cancer (mCRPC). (2014) (23)
- Safety and efficacy of nivolumab in metastatic renal cell carcinoma (mRCC): Results from the NIVOREN GETUG-AFU 26 study. (2018) (23)
- Survival benefit from first docetaxel treatment for cabazitaxel plus prednisone compared with mitoxantrone plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in the TROPIC trial. (2011) (22)
- Results of the FLAC European Database of Metastatic Castration‐Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor–Targeted Agents (2018) (22)
- Cancer de la prostate (2005) (22)
- Drug management of prostate cancer: prevalence and consequences of renal insufficiency. (2009) (22)
- Impact of Cabazitaxel (CBZ) + Prednisone (P; CBZP) on Overall Survival (OS) At 2 Yrs and in Patients (PTS) with Aggressive Disease: Post-Hoc Analyses of Tropic Trial (2012) (21)
- 4503 ORAL Sunitinib in metastatic renal cell carcinoma (mRCC): preliminary assessment of safety and efficacy in an expanded access trial with subpopulation analysis (2007) (20)
- 1O Clinical outcomes in post-operative ctDNA-positive muscle-invasive urothelial carcinoma (MIUC) patients after atezolizumab adjuvant therapy (2020) (20)
- Salvage therapy with bevacizumab-sunitinib combination after failure of sunitinib alone for metastatic renal cell carcinoma: a case series. (2009) (20)
- The role of rechallenge with targeted therapies in metastatic renal-cell carcinoma (2015) (20)
- Management of Painful Pelvic Bone Metastasis of Renal Cell Carcinoma Using Embolization, Radio-frequency Ablation, and Cementoplasty: A Prospective Evaluation of Efficacy and Safety (2014) (20)
- Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort (2019) (20)
- Enhance the Immune Checkpoint Inhibitors Efficacy with Radiotherapy Induced Immunogenic Cell Death: A Comprehensive Review and Latest Developments (2021) (20)
- Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort (2019) (20)
- Risk of Hormone Escape in a Human Prostate Cancer Model Depends on Therapy Modalities and Can Be Reduced by Tyrosine Kinase Inhibitors (2012) (20)
- Are tyrosine kinase inhibitors still active in patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus? Experience of 36 patients treated in France in the RECORD-1 Trial. (2013) (20)
- Expression of EPHRIN-A1, SCINDERIN and MHC class I molecules in head and neck cancers and relationship with the prognostic value of intratumoral CD8+ T cells (2013) (19)
- Prevalence of renal insufficiency in cancer patients: Data from the IRMA-2 study. (2016) (19)
- Effect of denosumab on prolonging bone-metastasis-free survival (BMFS) in men with nonmetastatic castrate-resistant prostate cancer (CRPC) presenting with aggressive PSA kinetics. (2012) (19)
- Bleomycin-Induced Pneumonitis in the Treatment of Ovarian Sex Cord–Stromal Tumors: A Systematic Review and Meta-analysis (2015) (19)
- Sunitinib for the treatment of benign and malignant neoplasms from von Hippel-Lindau disease: A single-arm, prospective phase II clinical study from the PREDIR group (2016) (19)
- Is intravenous (iv) IL2 superior to subcutaneous (sc) IL2 in good prognosis patients (pts) with metastatic renal cell carcinoma (MRCC) receiving a combination of IL2 and alpha interferon (IFN)? Results of the prospective randomized PERCY Duo trial. (2006) (18)
- [Cancer immunotherapy: Rational and recent breakthroughs]. (2016) (18)
- Matching-Adjusted Indirect Comparison of Health-Related Quality of Life and Adverse Events of Apalutamide Versus Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer (2019) (18)
- 257 UPDATED DATA FROM A PHASE 3 TRIAL OF EVEROLIMUS (RAD001) VERSUS PLACEBO IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (2009) (18)
- Evolution of renal function in patients treated with antiangiogenics after nephrectomy for renal cell carcinoma. (2011) (18)
- Reversible encephalopathy syndrome secondary to sunitinib for metastatic renal cell carcinoma patient (2007) (18)
- Safety and efficacy of nivolumab in metastatic renal cell carcinoma (mRCC): Final analysis from the NIVOREN GETUG AFU 26 study. (2019) (17)
- Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer (2019) (17)
- New Insights into the Management of Renal Cell Cancer (2012) (17)
- A randomized phase II study of GDC-0980 versus everolimus in metastatic renal cell carcinoma (mRCC) patients (pts) after VEGF-targeted therapy (VEGF-TT). (2014) (17)
- Anaphylactic reaction after a first filgrastim (granulocyte-colony stimulating factor) injection. (1995) (16)
- Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature. (2017) (16)
- Effect of G-CSF prophylaxis on the occurrence of neutropenia in men receiving cabazitaxel plus prednisone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in the TROPIC study. (2011) (16)
- Complete remission of pulmonary metastases of Bellini duct carcinoma with cisplatin, gemcitabine and bevacizumab (2012) (16)
- Trastuzumab (T) combined with standard chemotherapy in HER+ metastatic bladder cancer (BC) patients: Interim safety results of a prospective randomized phase II study (2007) (16)
- Impact of renal insufficiency on cancer survival: Results of the IRMA-2 study. (2009) (15)
- Sunitinib in metastatic renal cell carcinoma (mRCC) patients (pts) with brain metastases (mets): data from an expanded access trial (2008) (15)
- Immune-related adverse events: a retrospective look into the future of oncology in the intensive care unit (2020) (15)
- A Therapeutic Her2/neu Vaccine Targeting Dendritic Cells Preferentially Inhibits the Growth of Low Her2/neu–Expressing Tumor in HLA-A2 Transgenic Mice (2016) (15)
- Prognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agents (2014) (14)
- Rechallenge with mTOR Inhibitors in Metastatic Renal Cell Carcinoma Patients Who Progressed on Previous mTOR Inhibitor Therapy (2013) (14)
- [Angiogenesis inhibition: review of the activity of sorafenib, sunitinib and bevacizumab]. (2010) (14)
- A subgroup analysis of the TROPIC trial exploring reason for discontinuation of prior docetaxel and survival outcome of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC). (2011) (14)
- PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma (2020) (14)
- Dynamic contrast-enhanced CT (DCE-CT) as an early biomarker of response in metastatic renal cell carcinoma (mRCC) under anti-angiogenic treatment (2007) (14)
- mTOR-inhibitor treatment of metastatic renal cell carcinoma: contribution of Choi and modified Choi criteria assessed in 2D or 3D to evaluate tumor response (2015) (14)
- Sunitinib Prior to Planned Nephrectomy in Metastatic Renal Cell Carcinoma: Angiogenesis Biomarkers Predict Clinical Outcome in the Prospective Phase II PREINSUT Trial (2018) (14)
- Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA (2021) (14)
- The Tumor Antigen Cyclin B1 Hosts Multiple CD4 T Cell Epitopes Differently Recognized by Pre-Existing Naive and Memory Cells in Both Healthy and Cancer Donors (2015) (14)
- Learning spatiotemporal piecewise-geodesic trajectories from longitudinal manifold-valued data (2017) (13)
- Safety and efficacy of 2‐weekly cabazitaxel in metastatic castration‐resistant prostate cancer (2018) (13)
- Predictors of falls and fractures in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with apalutamide (APA) plus ongoing androgen deprivation therapy (ADT). (2019) (13)
- Effect of denosumab on prolonging bone-metastasis-free survival (BMFS) in men with nonmetastatic castrate-resistant prostate cancer (CRPC) presenting with aggressive PSA kinetics. (2012) (13)
- Supportive care organisation in France: an in depth study by the French speaking association for supportive care in cancer (AFSOS). (2013) (13)
- Update on the most promising biomarkers of response to immune checkpoint inhibitors in clear cell renal cell carcinoma (2021) (12)
- An ambispective observational study in the safety and efficacy of abiraterone acetate in the French temporary authorizations for use (ATU): Predictive parameters of response. (2012) (12)
- A simple HPLC-UV method for quantification of enzalutamide and its active metabolite N-desmethyl enzalutamide in patients with metastatic castration-resistant prostate cancer. (2017) (12)
- [Cabazitaxel for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: the TROPIC study in France]. (2012) (12)
- Real-world Experience With Sunitinib Treatment in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to Risk Score. (2019) (12)
- Patient-reported outcomes (PROs) in IMmotion151: Atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC). (2018) (12)
- Randomized phase II study of nintedanib in metastatic castration-resistant prostate cancer postdocetaxel (2014) (12)
- Pericardial effusion under nivolumab: case-reports and review of the literature (2019) (11)
- Soluble CD146 is a predictive marker of pejorative evolution and of sunitinib efficacy in clear cell renal cell carcinoma (2018) (11)
- Updated analysis of progression-free survival with first subsequent therapy (PFS2) and safety in the SPARTAN study of apalutamide (APA) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC). (2019) (11)
- Abstract 2605: Androgen receptor (AR) anomalies and efficacy of apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the phase 3 SPARTAN study (2018) (11)
- Impact of Patient- and Clinician-Reported Cumulative Toxicity on Quality of Life in Patients With Metastatic Castration-Naïve Prostate Cancer. (2018) (11)
- Polymorphisms in the Von Hippel–Lindau Gene Are Associated With Overall Survival in Metastatic Clear‐Cell Renal‐Cell Carcinoma Patients Treated With VEGFR Tyrosine Kinase Inhibitors (2018) (11)
- More than 4 years of progression-free survival in a patient with metastatic renal cell carcinoma treated sequentially with sunitinib, everolimus, sorafenib, and temsirolimus. (2010) (11)
- Serum PSA half‐life as a predictor of survival for hormone‐refractory prostate cancer patients: Modelization using a standardized set of response criteria (2007) (11)
- Phase 2 study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC). (2021) (11)
- Advances in the management of high‐risk localised and metastatic prostate cancer (2012) (11)
- Clinical progression at initiation of a life-extending therapy (LET) in metastatic castration-resistant prostate cancer (mCRPC) is associated with a poor prognosis, whatever the treatment-line: Results of the CATS retrospective registry. (2019) (11)
- Survival Outcomes From a Cumulative Analysis of Worldwide Observational Studies on Sequential Use of New Agents in Metastatic Castration-Resistant Prostate Cancer. (2019) (11)
- Neoadjuvant Dose-Dense Gemcitabine plus Docetaxel and Vinorelbine plus Epirubicin for Operable Breast Cancer (2011) (11)
- Patient‐reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma (2020) (11)
- Primary Renal Tumour Response in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma: Results from the GETUG-AFU 26 NIVOREN Trial. (2021) (11)
- Retrospective registry evaluating the PSA flare phenomenon with cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC). (2013) (11)
- Metastatic renal cell carcinoma (mRCC): Relationship between initial non-renal RECIST-target metastases hypoxia, change after 1 month of sunitinib, and therapeutic response: An 18F-MISO PET-CT study. (2010) (11)
- Supportive Care Organization in France: a national in-depth survey among patients and oncologists (2017) (11)
- Docetaxel versus mitoxantrone as first-line chemotherapy for hormone-refractory prostate cancer (HRPC) patients. A meta-analysis of 3-year overall survival results (2005) (11)
- Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma (2020) (10)
- PD-1 blockade in solid tumors with defects in polymerase epsilon. (2022) (10)
- Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials (2016) (10)
- 964 CLINICAL BENEFIT OF SORAFENIB IN THE ELDERLY WITH ADVANCED RENAL CELL CARCINOMA: SUBGROUP ANALYSIS OF THE APPROACHES IN RENAL CANCER GLOBAL EVALUATION TRIAL (TARGETS) (2007) (10)
- Efficacy of cabazitaxel rechallenge in heavily treated patients with metastatic castration-resistant prostate cancer. (2018) (10)
- Efficacy of cabozantinib (C) vs everolimus (E) in patients (pts) with advanced renal cell carcinoma (RCC) and bone metastases (mets) from the phase III METEOR study. (2016) (10)
- Cumulative meta-analysis of randomized trials comparing gemcitabine-based chemotherapy versus gemcitabine alone in patients with advanced or metastatic pancreatic cancer (PC) (2005) (10)
- [PD-1 and PDL-1 expression in cancer: significance and prognostic value]. (2013) (10)
- [Targeting the gene of glucose metabolism for the treatment of advanced gliomas]. (1998) (10)
- Comparative Efficacy of First-Line Immune-Based Combination Therapies in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis (2020) (10)
- [Metastatic kidney cancer: new therapeutic approaches]. (2002) (10)
- The Immunoscore in Localized Urothelial Carcinoma Treated with Neoadjuvant Chemotherapy: Clinical Significance for Pathologic Responses and Overall Survival (2021) (9)
- Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer (2012) (9)
- 7049 POSTER Management of Metastatic Castration-resistant Prostate Cancer (mCRPC) After an Initial Good Response to First-line Docetaxel (D) -a Retrospective Study on 270 Patients (pts) (2011) (9)
- Open-label phase II to evaluate the efficacy of NEoadjuvant dose-dense MVAC In cOmbination with durvalumab and tremelimumab in muscle-invasive urothelial carcinoma: NEMIO. (2020) (9)
- Results of the MARS study on the management of antiangiogenics’ renovascular safety in ovarian cancer. (2013) (9)
- Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group. (2019) (9)
- Denosumab or zoledronic acid (ZA) therapy on pain interference and cancer-specific quality of life (CSQoL) in patients with castrate-resistant prostate cancer (CRPC) and bone metastases (BM). (2014) (9)
- Impact of prior endocrine therapy on radiographic progression-free survival (rPFS) in patients (pts) with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302. (2014) (9)
- Baseline covariates impacting overall survival (OS) in a phase III study of men with bone metastases from castration-resistant prostate cancer. (2012) (9)
- Everolimus in metastatic renal cell carcinoma (mRCC): Subgroup analysis of patients (pts) with one versus two prior vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) therapies enrolled in the phase III RECORD-1 study. (2011) (9)
- Ten‐year outcome of curative “exclusive” chemotherapy in N0M0 squamous cell carcinoma of the larynx and pharynx with complete clinical response (2019) (9)
- Late-Onset Giant Cell Myocarditis Due to Enterovirus During Treatment With Immune Checkpoint Inhibitors (2020) (9)
- Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study. (2022) (9)
- Prognostic Impact of Baseline Serum C-Reactive Protein in Metastatic Renal Cell Carcinoma Patients Treated With Sunitinib (2014) (8)
- Prognostic Value of Baseline Neutrophil‐to‐Lymphocyte Ratio in Metastatic Urothelial Carcinoma Patients Treated With First‐line Chemotherapy: A Large Multicenter Study (2017) (8)
- Extreme hypomagnesemia: characteristics of 119 consecutive inpatients (2018) (8)
- Final results from ACIS, a randomized, placebo (PBO)-controlled double-blind phase 3 study of apalutamide (APA) and abiraterone acetate plus prednisone (AAP) versus AAP in patients (pts) with chemo-naive metastatic castration-resistant prostate cancer (mCRPC). (2021) (8)
- Efficacy and safety of everolimus in elderly patients (pts) with metastatic renal cell carcinoma (mRCC). (2010) (8)
- Long-Term Response and Postsurgical Complete Remissions After Treatment With Sunitinib Malate, an Oral Multitargeted Receptor Tyrosine Kinase Inhibitor, in Patients With Metastatic Renal Cell Carcinoma (2011) (8)
- Treatment of patients with advanced or bulky Hodgkin disease with a 12‐week doxorubicin, bleomycin, vinblastine, and dacarbazine‐like chemotherapy regimen followed by extended‐field, full‐dose radiotherapy (2002) (8)
- Renal insufficiency in cancer patients: Prevalence and implications on anticancer drugs management. Results of the IRMA study. (2006) (8)
- What is the best treatment option for second line in long responders to the first-line TKI in metastatic renal cell carcinoma (mRCC) patients (pts): TKI-TKI or TKI-mTORi? A European retrospective study. (2012) (8)
- Docetaxel-based chemotherapy in elderly patients (>= 75 years) with castration resistant prostate cancer (CRPC): A French National study of 175 patients (2008) (8)
- Le cancer du sein (1997) (8)
- 923TiPA phase 2 BIOmarker driven trial with Nivolumab and Ipilimumab or VEGFR tKi in naïve metastatic Kidney cancer: the BIONIKK trial (2017) (8)
- Apalutamide (APA) and overall survival (OS) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Updated results from the phase III SPARTAN study (2019) (8)
- Renal malacoplakia: Case report of a differential diagnosis for renal cell carcinoma (2012) (8)
- Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma (2017) (8)
- Biomarkers from the tumor microenvironment to predict clinical response to checkpoint inhibitors (2014) (8)
- Quality of Life and Pain During Treatment of Metastatic Castration-resistant Prostate Cancer With Cabazitaxel In Routine Clinical Practice. (2020) (8)
- Imaging Response of Antiangiogenic and Immune-Oncology Drugs in Metastatic Renal Cell Carcinoma (mRCC): Current Status and Future Challenges (2017) (8)
- Sunitinib Global Expanded-Access Trial in Metastatic Renal Cell Carcinoma (MRCC) – Final Results (2012) (7)
- Pleural effusion is a negative prognostic factor for immunotherapy in patients with non-small cell lung cancer (NSCLC): The pluie study. (2021) (7)
- 73P Association between homologous recombination repair mutations and response to pembrolizumab (pembro) plus olaparib (ola) in metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A biomarker analysis (2021) (7)
- Practical aspects of metastatic castration‐resistant prostate cancer management: patient case studies (2012) (7)
- Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A efficacy, safety, and biomarker results. (2020) (7)
- Resistance to cancer immunotherapy in metastatic renal cell carcinoma (2020) (7)
- 99 The impact of bone metastases on pain: Results from a phase III denosumab study in men with nonmetastatic castration-resistant prostate cancer (2013) (7)
- [Nausea and vomiting in cancer patients]. (2006) (7)
- Results of a randomized phase II study of irofulven in hormone-refractory prostate cancer patients that have failed first-line docetaxel treatment (2007) (7)
- Nivolumab in metastatic nonclear cell renal cell carcinoma: First results of the AcSe prospective study. (2020) (7)
- 246 OVERALL SURVIVAL WITH SUNITINIB VERSUS INTERFERON-ALFA (IFN-□) AS FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA (MRCC) (2009) (7)
- Phase II study of vlnorelbine in patients with hormone refractory prostate cancer (1997) (7)
- Cost-effectiveness Analysis of Innovative Therapy for Patients with Newly Diagnosed Hormone-Sensitive Metastatic Prostate Cancer. (2021) (7)
- Efficacy of apalutamide (APA) plus ongoing androgen deprivation therapy (ADT) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) and baseline (BL) comorbidities (CM). (2019) (7)
- Epoetin β Once-Weekly Therapy in Anemic Patients with Solid Tumors and Non-Myeloid Hematological Malignancies Receiving Chemotherapy (2008) (7)
- Precision immunity: Immunoscore and neoadjuvant treatment in bladder cancer (2021) (6)
- 1098 Phase III study of neovastat in metastatic renal cell carcinoma patients refractory to immunotherapy (2003) (6)
- Autologous dendritic cell immunotherapy (DCVAC/PCa) added to docetaxel chemotherapy in a Phase III trial (viable) in men with advanced (mCRPC) prostate cancer (2015) (6)
- [Prostate cancer: update]. (2005) (6)
- Hormone escape is associated with genomic instability in a human prostate cancer model (2009) (6)
- Q-TWiST analysis of patients with metastatic castrate naive prostate cancer treated by androgen deprivation therapy with or without docetaxel in the randomised phase III GETUG-AFU 15 trial. (2017) (6)
- Multicenter Randomized Phase 2 Trial of Gemcitabine – Platinum with or without Trastuzumab (T) in Advanced / Metastatic Urothelial Carcinoma (A/MUC) with HER2 Overexpression (2012) (6)
- Phase II trial of sunitinib in renal cell cancer with untreated brain metastases. (2011) (6)
- MP34-20 METASTASIS-FREE SURVIVAL (MFS) IN NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) PATIENTS (PTS) WITH PROSTATE-SPECIFIC ANTIGEN (PSA) DECLINE TO < 0.2 NG/ML FOLLOWING APALUTAMIDE (APA) TREATMENT: POST HOC RESULTS FROM THE PHASE 3 SPARTAN STUDY (2019) (6)
- HER2 status in urothelial bladder cancer (UC): screening of patients eligible for a phase II randomized study of gemcitabine plus platinum salt with or without trastuzumab (2005) (6)
- Peritoneal Carcinomatosis in Germ-Cell Tumor: Relations With Retroperitoneal Lymph Node Dissection (2000) (6)
- Indocyanine green for sentinel lymph node detection in early breast cancer: Prospective evaluation of detection rate and toxicity—The FLUOBREAST trial (2020) (6)
- PSA response and early PSA progression evaluated in patients randomized in a phase III trial comparing androgen-deprivation therapy (ADT) plus docetaxel versus ADT alone in hormone-naive metastatic prostate cancer (GETUG-AFU 15/0403). (2011) (6)
- Bayesian predictive model to assess BRCA2 mutational status according to clinical history: Early onset, metastatic phenotype or family history of breast/ovary cancer (2021) (6)
- Soluble epidermal growth factor receptor (EGFR) and HER-2 monitoring in a Phase II combination of gefitinib (ZD1839) and docetaxel for non-small-cell lung cancer (NSCLC). (2004) (6)
- 1L pembrolizumab (pembro) versus chemotherapy (chemo) for choice-of-carboplatin patients with advanced urothelial carcinoma (UC) in KEYNOTE-361. (2021) (6)
- Dose finding and safety analysis of inecalcitol in combination with a docetaxel-prednisone regimen in hormone-refractory prostate cancer (HRPC) patients. (2009) (6)
- Impact of progression at baseline and on-treatment progression events in three large prostate cancer trials. (2019) (6)
- Clinical Benefit of Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma: The French Retrospective SECTOR Study. (2016) (5)
- 732P Cabozantinib in non-clear cell metastatic renal cell carcinoma and sarcomatoid renal cell carcinoma: Real-world data from the CABOREAL study (2020) (5)
- 612P Pembrolizumab (pembro) plus olaparib in patients with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Update of KEYNOTE-365 cohort A with a minimum of 11 months of follow-up for all patients (2021) (5)
- Metastatic Renal Medullary and Collecting Duct Carcinoma in the Era of Antiangiogenic and Immune Checkpoint Inhibitors: A Multicentric Retrospective Study (2022) (5)
- Tumor molecular characteristics in patients (pts) with international metastatic renal cell carcinoma database consortium (IMDC) good (G) and intermediate/poor (I/P) risk. (2018) (5)
- Pain Progression at Initiation of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Post Hoc Analysis of the PROSELICA Study (2021) (5)
- MP34-19 EFFICACY AND SAFETY OF APALUTAMIDE (APA) IN NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) PATIENTS (PTS) WITH OR WITHOUT PRIOR RADICAL PROSTATECTOMY (RP) AND/OR EXTERNAL RADIOTHERAPY (XRT): POST HOC ANALYSIS OF SPARTAN (2019) (5)
- 724P A prospective phase II study of gemcitabine plus platinum in combination with bevacizumab for metastatic renal medullary and collecting duct carcinoma (GETUG-AFU 24, BEVABEL trial) (2020) (5)
- Prostate cancer: Cabazitaxel—the taxane of choice in the new mCRPC landscape? (2014) (5)
- Molecular determinants of prostate specific antigen (PSA) kinetics and clinical response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in SPARTAN. (2020) (5)
- Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next? (2019) (5)
- 860 PHASE III RANDOMIZED TRIAL OF SUNITINIB MALATE VERSUS INTERFERON-ALFA AS FIRST-LINE SYSTEMIC THERAPY FOR PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (2007) (5)
- Treatment Decisions for Advanced Genitourinary Cancers: From Symptoms to Risk Assessment (2009) (5)
- Decrease of Pro-Angiogenic Monocytes Predicts Clinical Response to Anti-Angiogenic Treatment in Patients with Metastatic Renal Cell Carcinoma (2021) (5)
- Burden of metastatic hormone-sensitive prostate cancer to identify men more likely to benefit from early docetaxel. (2017) (5)
- Regional differences observed in the phase 3 trial (ELM-PC 5) with orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel. (2014) (5)
- Clinical benefits of non‐taxane chemotherapies in unselected patients with symptomatic metastatic castration‐resistant prostate cancer after docetaxel: the GETUG‐P02 study (2015) (5)
- REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study (2022) (5)
- Docetaxel rechallenge in patients with metastatic castration-resistant prostate cancer (2015) (5)
- Age-related efficacy and safety of apalutamide (APA) plus ongoing androgen deprivation therapy (ADT) in subgroups of patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Post hoc analysis of SPARTAN. (2019) (5)
- Complete remission with TKI in renal cell carcinomas: Experience in 65 patients of the French Kidney Cancer Group. (2010) (5)
- LBA26 Phase II study of the oral HIF-2α inhibitor MK-6482 for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC): Update on RCC and non-RCC disease (2020) (5)
- A preclinical therapeutic schedule optimizing docetaxel plus estramustine administration in prostate cancer (2010) (5)
- Efficacy and tolerance of treatments received beyond progression in men with metastatic hormone-naive prostate cancer treated with androgen deprivation therapy (ADT) with or without docetaxel in the GETUG-AFU 15 phase III trial. (2016) (5)
- [Tim-3: a novel biomarker and therapeutic target in oncology]. (2018) (5)
- Renal Carcinoma and Angiogenesis: Therapeutic Target and Biomarkers of Response in Current Therapies (2022) (5)
- Results of the MARS study on the management of antiangiogenics’ renovascular safety in renal cell carcinoma. (2014) (4)
- Fibroblast Growth Factor Receptor‐2 Polymorphism rs2981582 is Correlated With Progression‐free Survival and Overall Survival in Patients With Metastatic Clear‐cell Renal Cell Carcinoma Treated With Sunitinib (2019) (4)
- Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database. (2019) (4)
- Prostate-specific antigen doubling-time (PSA DT) before onset of chemotherapy as survival predictor for hormone refractory prostate cancer (HRPC) patients (2005) (4)
- A combination docetaxel-capecitabine in patients (pts) with hormone refractory advanced prostate cancer. (2004) (4)
- Fuhrman grade and concomitant bisphosphonates as additional prognostic factors in metastatic renal cell carcinoma with bone metastases treated with sunitinib. (2011) (4)
- Abstract P3-15-06: Results of the MARS study on the management of antiangiogenics’ renovascular safety in breast cancer (2013) (4)
- Advances in Brief Alterations of the DNA Repair Gene OGG 1 in Human Clear Cell Carcinomas of the Kidney 1 (2000) (4)
- SUNITINIB AS FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA (MRCC): UPDATED RESULTS AND ANALYSIS OF PROGNOSTIC FACTORS FROM A PHASE III RANDOMISED TRIAL (2008) (4)
- Plasma CD27, a surrogate of the intratumoral CD27-CD70 interaction, correlates with immunotherapy resistance in renal cell carcinoma. (2022) (4)
- Validation of the lung immune prognostic index (LIPI) in patients with metastatic renal cell carcinoma treated with nivolumab in the GETUG-AFU 26 NIVOREN trial. (2020) (4)
- [Antiangiogenics: new therapeutic standards in metastatic kidney cancer]. (2008) (4)
- Assessment of frozen glove use in the prevention of docetaxel induced onycholysis and cutaneous reaction. Results of a multicenter case-control study (2004) (4)
- 711 EFFECTS OF DENOSUMAB AND ZOLEDRONIC ACID ON PAIN INTERFERENCE WITH DAILY FUNCTIONING IN PATIENTS WITH CASTRATE-RESISTANT PROSTATE CANCER (2011) (4)
- Randomized phase II trial of irofulven (IROF)/prednisone (P), IROF/capecitabine (C)/P or mitoxantrone (M)/P in docetaxel-pretreated hormone refractory prostate cancer (HRPC) patients (pts). (2006) (4)
- 718P A phase II study of patients with advanced or metastatic renal cell carcinoma (mRCC) receiving pazopanib after previous checkpoint inhibitor treatment (2020) (4)
- Evaluation of the response to cabazitaxel of a docetaxel-responsive hormone-refractory prostate tumor xenograft model (HID28). (2012) (4)
- 722P Cabozantinib in elderly patients: Results from a subanalysis of the CABOREAL study (2020) (4)
- Combining docetaxel with estramustine: back to the future? (2009) (4)
- Efficacy of cabazitaxel (CABA) rechallenge in heavily-treated patients with metastatic castration-resistant prostate cancer (mCRPC). (2017) (4)
- Autologous dendritic cell vaccination (DCVAC/PCa) added to docetaxel chemotherapy in a double-blind, randomized phase III trial (VIABLE) in men with advanced (mCRPC) prostate cancer. (2015) (4)
- A therapeutic Her 2 / neu vaccine targeting dendritic cells preferentially inhibits the growth of low Her 2 / neu-expressing tumor in HLA-A 2 transgenic mice (2016) (4)
- Renal insufficiency in bone metastasis cancer patients: Prevalence and implications on anticancer drugs management, subgroup analysis of the IRMA study (2007) (4)
- Charting Recent Progress and Challenges in Metastatic Castration-resistant Prostate Cancer: Is There an Optimal Treatment Sequence? (2016) (4)
- Treatments Outcomes in Histological Variants and Non-Urothelial Bladder Cancer: Results of a Multicenter Retrospective Study (2021) (4)
- Dose-finding and efficacy phase II study of inecalcitol, a new VDR agonist, in combination with docetaxel-prednisone regimen for castration-resistant prostate cancer (CRPC) patients (pts). (2011) (4)
- High level of activity of nivolumab anti-PD-1 immunotherapy and favorable outcome in metastatic/refractory MSI-H non-colorectal cancer: Results of the MSI cohort from the French AcSé program (2019) (4)
- 816PDCLINICAL ACTIVITY OF SUNITINIB RECHALLENGE IN METASTATIC RENAL CELL CARCINOMA (MRCC) - RESULTS OF THE RESUME STUDY. (2014) (4)
- Prognostic impact of baseline serum C-reactive protein in metastatic renal cell carcinoma treated with sunitinib. (2013) (4)
- Comment on: Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma (2008) (4)
- First-line use of cabazitaxel in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC): A three-arm study in comparison with docetaxel. (2012) (4)
- Denosumab and zoledronic acid treatment in patients with genitourinary cancers and bone metastases. (2013) (4)
- Homophilic anchorage of brain-hexokinase to mitochondria-porins revealed by specific-peptide antibody cross recognition. (2004) (4)
- A phase III, randomized, open-label, study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy (NHT) in patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC). (2021) (4)
- NEURO/MEDICAL ONCOLOGY (2013) (4)
- SAFETY AND EFFICACY OF SUNITINIB IN AN EXPANDED-ACCESS TRIAL OF METASTATIC RENAL CELL CARCINOMA (MRCC): UPDATED RESULTS AND SUBPOPULATION ANALYSIS (2008) (4)
- Corrected area under serum hemoglobin curve (Hb c-AUC) as a predictor of maximal hemoglobin response after erythropoietin (rHuEpo) treatment in chemotherapy induced anemia patients. (2004) (3)
- 657MO Antibiotic (ATB) therapy and outcome from nivolumab (N) in metastatic renal cell carcinoma (mRCC) patients (pts): Results of the GETUG-AFU 26 NIVOREN multicentric phase II study (2021) (3)
- 943 PAIN INTERFERENCE WITH DAILY FUNCTIONING IN PATIENTS WITH CASTRATE-RESISTANT PROSTATE CANCER: A COMPARISON OF DENOSUMAB AND ZOLEDRONIC ACID (2012) (3)
- [Renovascular safety of bevacizumab in breast cancer patients. The prognostic value of hypertension and proteinuria]. (2015) (3)
- Phase II trial of afatinib in patients with advanced/metastatic urothelial carcinoma (UC) with genetic alterations in ERBB receptors 1-3 who failed on platinum-based chemotherapy (CT). (2018) (3)
- 7003 ORAL Denosumab and Bone Metastasis-free Survival in Men With Castrate-resistant Prostate Cancer – Subgroup Analyses From an International, Double-blind, Randomized, Phase 3 Trial (2011) (3)
- Comparative Efficacy of First-Line Immune-Based Combination Therapies in Metastatic Renal Cell Carcinoma. A Systematic Review and Network Meta-Analysis. (2020) (3)
- Impact of G-CSF prophylaxis on the occurrence of neutropenia in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel. (2011) (3)
- Anti-VEGF therapies, cancer and renal function (2008) (3)
- What is the real impact of bone pain on survival of hormone-refractory prostate cancer (HRPC) patients treated with docetaxel? (2007) (3)
- 2541 Updated results of the FLAC European database of metastatic castration resistant prostate cancer (mCRPC) patients (pts) treated with life extending therapies in post-docetaxel (D) setting (2015) (3)
- An analysis of health-related quality of life in the phase III PROSELICA and FIRSTANA studies assessing cabazitaxel in patients with metastatic castration-resistant prostate cancer (2021) (3)
- Phase III study of addition of docetaxel (D) to hormonal therapy (HT) versus HT alone in nonmetastatic high-risk prostate cancer (PC) patients (pts): Final results on PSA progression-free survival. (2011) (3)
- Human and murine prostate basal/stem cells are not direct targets of prolactin. (2015) (3)
- 1090 CLINICAL BENEFIT OF CABAZITAXEL PLUS PREDNISONE IN THE TROPIC TRIAL IN MEN WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC) WHO PROGRESSED AFTER DOCETAXEL-BASED TREATMENT (2011) (3)
- Association of plasma cell-free DNA concentration [cfDNA] with outcome from taxane therapy (TT) for castration resistant prostate cancer (CRPC). (2016) (3)
- A phase II prospective study of gemcitabine and platin-based combination as first-line chemotherapy for metastatic Bellini duct carcinoma patients. Results of GETUG study (2005) (3)
- Genitourinary tumors, prostate (2012) (3)
- Clinical recommendations in the management of advanced prostate cancer: International Gastrointestinal, Liver and Uro-oncology (IGILUC 2019) experts (2020) (3)
- Cabazitaxel schedules in metastatic castration-resistant prostate cancer: a review. (2020) (3)
- 81 Updated results of the phase 3 AXIS trial: Axitinib vs sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC) (2012) (3)
- [Management of side-effects of targeted therapies in renal cancer: endocrine side-effects and metabolic disorders]. (2011) (3)
- [Antiangiogenic treatment and kidney cancer: ongoing trials and future perspectives]. (2008) (3)
- A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal cell carcinoma (RCC). (2006) (3)
- [New targeted therapies in hormone-refractory prostate cancer]. (2007) (3)
- Renal insufficiency in cancer patients: Prevalence and implications on anticancer drugs management. Results of the IRMA study (2006) (3)
- Controversies and consensus in the innovation access for cancer therapy in the European countries: on the subject of metastatic prostate cancer (2017) (3)
- A phase I study of sorafenib in association with docetaxel-prednisone in chemonaive metastatic castration-resistant prostate cancer. (2009) (3)
- 789PPROGNOSTIC FACTORS FOR SURVIVAL AND SEQUENCING OF LIFE-EXTENDING THERAPIES IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC) PATIENTS (PTS) IN POST-DOCETAXEL (D) SETTING. (2014) (3)
- Everolimus or sunitinib as first-line treatment of metastatic papillary renal cell carcinoma: A retrospective study of the GETUG group (Groupe d'Etude des Tumeurs Uro-Génitales). (2021) (3)
- 299 POSTER Randomized phase II trial of irofulven/prednisone, irofulven/capecitabine/prednisone, or mitoxantrone/prednisone in hormone refractory prostate cancer (HRPC) patients failing first-line docetaxel: preliminary results (2006) (3)
- Sequencing in metastatic castration-resistant prostate cancer (mCRPC): Updated results of the FLAC International Database. (2017) (3)
- [Renal carcinoma: point on treatment of brain metastasis]. (2012) (3)
- Prognostic factors for survival in the phase III TROPIC trial. (2012) (2)
- Identification of prognostic groups in patients with hormone-sensitive metastatic prostate cancer at the present time: An analysis of the GETUG 15 phase III trial. (2013) (2)
- Pharmacokinetics (PK) and immunologic responses in a phase I/II study of a sustained release formulation of IL-2 in renal cell carcinoma (RCC) patients. (2006) (2)
- Brain Metastasis from Renal Carcinoma: Locoregional and Systemic Treatments (2015) (2)
- Severe Cellular Immunodeficiency Triggered by the CDK4/6 Inhibitor Palbociclib (2020) (2)
- Analysis of characteristics in patients (pts) with metastatic renal cell cancer (MRCC) who achieved a prolonged benefit from sunitinib or sorafenib (2008) (2)
- 1363MO Cabazitaxel every 2 weeks versus every 3 weeks in older patients with metastatic castration-resistant prostate cancer (mCRPC): The CABASTY randomized phase III trial (2022) (2)
- Soluble CD 146 is a predictive marker of pejorative evolution and of sunitinib efficacy in clear cell renal cell carcinoma (2018) (2)
- Dose-finding and efficacy phase II study of inecalcitol, a new VDR agonist, in combination with docetaxel-prednisone regimen for patients (pts) with castration-resistant prostate cancer (CRPC). (2011) (2)
- A pharmacogenomic scoring system predicting median time to progression (mTTP) on sunitinib (SUN) as first-line treatment in patients (pts) with metastatic renal cell carcinoma (mRCC). (2012) (2)
- MiTF/TFE Translocation Renal Cell Carcinomas: From Clinical Entities to Molecular Insights (2022) (2)
- A pharmacogenomic scoring system predicting median time to progression (mTTP) on sunitinib (SUN) as first-line treatment in patients (pts) with metastatic renal cell carcinoma (mRCC). (2012) (2)
- Prostate-specific antigen (PSA) kinetics in patients (pts) with advanced prostate cancer treated with apalutamide: Results from the TITAN and SPARTAN studies. (2020) (2)
- Cabozantinib‐nivolumab sequence in metastatic renal cell carcinoma: The CABIR study (2022) (2)
- Results of a first-in-human phase I study of INVAC-1, an optimized plasmid DNA encoding an inactive form of human telomerase reverse transcriptase (hTERT), in patients with advanced solid tumors. (2017) (2)
- 806TiPSPARTAN - A RANDOMIZED DOUBLE-BLIND, COMPARATIVE STUDY OF ARN-509 PLUS ANDROGEN DEPRIVATION THERAPY (ADT) VS ADT ALONE IN NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (M0-CRPC). (2014) (2)
- Long-term responders to everolimus: A subgroup analysis of the sector study. (2014) (2)
- Impact of corticosteroids on nivolumab activity in metastatic clear cell renal cell carcinoma (2019) (2)
- 433 Decrease of pro-angiogenic monocytes predicts clinical response to anti-angiogenic treatment in patients with metastatic renal cell carcinoma (mRCC) (2015) (2)
- Bone metastasis is associated with poor prognosis in metastatic papillary renal cell carcinoma patients treated with first agent angiogenesis inhibitors. (2020) (2)
- Apalutamide Compared with Darolutamide for the Treatment of Non-metastatic Castration-Resistant Prostate Cancer: Efficacy and Tolerability in a Matching-Adjusted Indirect Comparison (2021) (2)
- Treatment of metastatic castration-resistant prostate cancer (mCRPC); Survival by type of progression at initiation of treatment. (2018) (2)
- Controversies and consensus in the innovation access for cancer therapy in the European countries: on the subject of metastatic prostate cancer. (2017) (2)
- ABCB-1 and VEGFR-3 Single Nucleotide Polymorphisms (SNPs) and Outcome on Sunitinib (SUN) Treatment in Metastatic Clear Cell Renal Cell Carcinoma (RCC) (2011) (2)
- PROCHE: A program to monitor side effects among patients treated in a medical oncology outpatient unit. (2010) (2)
- Phase II study of the oral hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC). (2021) (2)
- Apalutamide and overall survival in patients with nonmetastatic castration-resistant prostate cancer: Updated results from the phase 3 SPARTAN study (2019) (2)
- LBA69 Belzutifan, a HIF-2α Inhibitor, for von Hippel-Lindau (VHL) disease-associated neoplasms: 36 months of follow-up of the phase II LITESPARK-004 study (2022) (2)
- PD34-11 PROSTATE-SPECIFIC ANTIGEN KINETICS IN PATIENTS WITH ADVANCED PROSTATE CANCER TREATED WITH APALUTAMIDE: RESULTS FROM THE TITAN AND SPARTAN STUDIES (2021) (2)
- Prognostic factors for survival in the phase III TROPIC trial. (2012) (2)
- Post hoc responder analysis of health-related quality of life (HRQL) in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel in the phase III PROSELICA and FIRSTANA trials. (2018) (2)
- What is the benfit of mTOR inhibitors (mTORi) rechallenge in metastatic renal clear cell carcinoma (mRCC) patients (pts) initially treated with TKI? (2012) (2)
- Cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC): Real-life use, effectiveness, safety, and quality of life (QoL) in the FUJI cohort. (2018) (2)
- Tim-3 expression on tumor-infiltrating PD-1 CD8T cells correlates with poor clinical outcome in renal cell carcinoma Running title: Tim-3 on intratumoral CD8T cells and poor outcome in RCC (2016) (2)
- Health-related quality of life (HRQoL) after progressive disease (PD) in SPARTAN: A phase III trial of apalutamide (APA) versus placebo (PBO) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC). (2018) (2)
- 681 DENOSUMAB DELAYS DEVELOPMENT OF MULTIPLE BONE METASTASES IN MEN WITH CASTRATE-RESISTANT PROSTATE CANCER (2012) (2)
- Patients' self-assessment of tolerance and quality of life during docetaxel-based chemotherapy: Results from a phase III trial in hormone-naive metastatic prostate cancer patients (GETUG-AFU 15/0403). (2010) (2)
- Early objective response may not be a prognostic factor of survival for patients with metastatic urothelial carcinoma: from a retrospective analysis of a cohort of 113 patients (2015) (2)
- 073 PROCHE: a program to improve patients healthcare in an outpatient medical oncology unit (2010) (2)
- Modeled Early Longitudinal PSA Kinetics Prognostic Value in Rising PSA Prostate Cancer Patients after Local Therapy Treated with ADT +/− Docetaxel (2022) (2)
- 7030 Dose finding and safety analysis of inecalcitol in combination with docetaxel-prednisone regimen in hormone-refractory prostate cancer (HRPC) patients (pts) (2009) (2)
- [Impact of molecular signatures on the choice of systemic treatment for metastatic kidney cancer]. (2020) (2)
- Efficacy of cabazitaxel, abiraterone, enzalutamide and docetaxel sequence in men with metastatic castration-resistant prostate cancer (mCRPC) in real life practice: The multinational, retrospective, observational CATS study (2016) (2)
- Patient-reported outcomes (PROs) in IMmotion150: Atezolizumab (atezo) alone or with bevacizumab (bev) versus sunitinib (sun) in first-line metastatic renal cell carcinoma (mRCC). (2019) (2)
- 7044 Pharmacokinetic analysis of two dosing schedules of the angiokinase inhibitor BIBF 1120 in patients with hormone-refractory prostate cancer who progressed after docetaxel treatment (2009) (2)
- Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Estimating mean overall survival (OS) for health economic analyses from a phase III trial (TROPIC). (2011) (2)
- 719 EVEROLIMUS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA: SUBGROUP ANALYSIS OF PATIENTS WITH A REDUCTION IN TUMOR BURDEN ENROLLED IN A RANDOMIZED, PLACEBO-CONTROLLED, PHASE II TRIAL (2011) (2)
- NEMIO: A randomized phase II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) + durvalumab +/- tremelimumab as neoadjuvant treatment in patients with bladder muscle-invasive urothelial carcinoma (2019) (2)
- 7115 POSTER DISCUSSION ABCB-1 and VEGFR-3 Single Nucleotide Polymorphisms (SNPs) and Outcome on Sunitinib (SUN) Treatment in Metastatic Clear Cell Renal Cell Carcinoma (RCC) (2011) (2)
- [Update on the use of estramustin in metastatic prostate cancer]. (2010) (2)
- Olecranon bursitis in patients treated with sunitinib for renal cell carcinoma (2010) (2)
- MP24-14 PEMBROLIZUMAB (PEMBRO) PLUS OLAPARIB IN PATIENTS WITH DOCETAXEL-PRETREATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC): UPDATED RESULTS FROM KEYNOTE-365 COHORT A WITH A MINIMUM OF 11 MONTHS OF FOLLOW-UP FOR ALL PATIENTS (2021) (2)
- [Bellini tumours]. (2011) (2)
- 1059P NEMIO: A randomized phase I-II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) + durvalumab +/- tremelimumab as neoadjuvant treatment in patients with bladder muscle-invasive urothelial carcinoma (2020) (2)
- 784ODocetaxel (D) with androgen suppression (AS) for high-risk localized prostate cancer (HrPC) patients (pts) who relapsed PSA after radical prostatectomy (RP) and/or radiotherapy (RT): A randomized phase III trial (2017) (2)
- Corrected area under serum PSA curve as a predictor of survival after chemotherapy for hormone-refractory prostate cancer (HRPC) patients. (2004) (1)
- Survival outcomes from a cumulative analysis from worldwide observational studies on sequential use of new agents (NAs) in metastatic castration-resistant prostate cancer (mCRPC) (CASTOR study). (2018) (1)
- Neutrophil to lymphocyte ratio (NLR) kinetics as predictors of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (NSCLC) patients treated with nivolumab (N) (2019) (1)
- Targeted Therapy ’ s Skin Toxicities after Immunotherapy : Skin Toxicity of Tyrosine Kinase Inhibitor Therapy Following Nilovumab Therapy for Metastatic Renal Cell Carcinoma (2016) (1)
- [MDR (Multiple Drug Resistant) type of resistance to chemotherapy in clinical practice]. (1996) (1)
- 247 SUNITINIB IN METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS (PTS) WITH BRAIN METASTASES (METS): DATA FROM AN EXPANDED-ACCESS STUDY (2009) (1)
- Relation between lactate dehydrogenase (LDH) during two first cycles in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib (SU) (2007) (1)
- Neuroendocrine carcinoma of the urinary bladder: A large analysis of the French GETUG consortium. (2018) (1)
- Long-term use of sunitinib in metastatic renal cell carcinoma: no unpleasant surprises about tolerability (2016) (1)
- Impact of subsequent therapy on survival in KEYNOTE-361: Pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as first-line therapy for advanced urothelial carcinoma (UC). (2021) (1)
- 880PBiomarkers before and after nephrectomy of locally advanced or metastatic renal cell carcinoma (RCC) treated with everolimus: Neorad phase 2 trial (PREDICT consortium) (2017) (1)
- Poster Session (Monday, 28 September)Translational ResearchPOSTER223 Predictive biomarkers in metastatic Renal Cell Carcinoma (mRCC) patients treated with neoadjuvant sunitinib (PREINSUT trial) (2015) (1)
- Nivolumab (N) treatment beyond progression in a real-world cohort of patients (pts) with metastatic renal cell carcinoma (mRCC) (2019) (1)
- How should we treat castration-resistant prostate cancer patients who have received androgen deprivation therapy (ADT) plus docetaxel upfront for hormone-sensitive diseae? Mature analysis of the GETUG-AFU 15 phase III trial (2016) (1)
- Abstracts the Metastasis Research Society-American Association for Cancer Research Conference on Metastasis (2008) (1)
- P09.05 Plasma CD27, a surrogate of intratumoral CD27-CD70 interaction, correlates with immunotherapy resistance in renal cancer (2021) (1)
- POD-11.01: Dose Finding and Safety Analysis of Inecalcitol in Combination with Docetaxel-Prednisone Regimen in Hormone-Refractory Prostate Cancer (HRPC) Patients (PTS) (2009) (1)
- 686P Angiogenesis related blood biomarkers of response to checkpoint inhibitors (IO) and VEGFR-TKI in metastatic renal cell carcinoma (mRCC): Results from the BIONIKK prospective trial (2021) (1)
- Management of antiangiogenics’ renovascular safety in breast cancer subgroup and intermediate results of the MARS study. (2012) (1)
- Phase II study of the cancer vaccine TG4010 in metastatic renal cell carcinoma (2005) (1)
- 735P Metastatic renal medullary and collecting duct carcinoma in the era of antiangiogenic and immune checkpoint inhibitors: A multicentric retrospective study (2020) (1)
- 1126 POSTER Epoetin beta once-weekly (QW) treatment in anaemic patients with solid tumour receiving chemotherapy (2007) (1)
- Efficacy and safety of immune checkpoint inhibitors (ICIs) for treatment of advanced solid tumours in octogenarian patients (2019) (1)
- MP70-11 IMPACT OF PRIOR ENDOCRINE THERAPY ON CLINICAL BENEFIT OF ABIRATERONE ACETATE IN PATIENTS WITH CHEMOTHERAPY-NAÏVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: RESULTS FROM COU-AA-302 (2014) (1)
- MP73-10 BONE TURNOVER MARKER LEVELS AND OUTCOMES IN MEN WITH PROSTATE CANCER AND BONE METASTASES TREATED WITH BONE ANTIRESORPTIVE AGENTS (2015) (1)
- Impact of nail toxicity on survival of patients with hormone-refractory prostate cancer (HRPC) treated with docetaxel. (2016) (1)
- Frozen sock use in the prevention of docetaxel-induced nails and skin toxicities: Results of a case-control study (2007) (1)
- What is the best treatment option for second line in long responders to the first-line TKI in metastatic renal cell carcinoma (mRCC) patients (pts): TKI-TKI or TKI-mTORi? A European retrospective study. (2012) (1)
- 7136 POSTER The Association Between Treatment (tx) Modifications Due to Adverse Events (AEs) and Overall Survival (OS) in Patients (pts) With Advanced Renal Cell Carcinoma (RCC) Treated With Sunitinib and Sorafenib: Results From a Multi-country Study in Europe (2011) (1)
- Efficacy and Safety of Concomitant Proton Pump Inhibitor and Nivolumab in Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study. (2022) (1)
- Association of statins and nivolumab activity in patients with metastatic renal cell carcinoma (mRCC): Results from the phase II nivoren—GETUG AFU 26 trial. (2021) (1)
- Site of metastasis in metastatic clear cell renal cell carcinoma (mccRCC) and outcome of treatment with sunitinib. (2010) (1)
- Nonmetastatic, high-risk prostate cancer patients with biochemical relapse after local treatment: A prospective, randomized phase III study comparing hormonal therapy {+/-} docetaxel--An analysis of final safety results. (2010) (1)
- Expression of EPHRIN-A 1 , SCINDERIN and MHC class I molecules in head and neck cancers and relationship with the prognostic value of intratumoral CD 8 + T cells (2013) (1)
- Early TKI-pharmokinetics and circulating tumor DNA (ctDNA) to predict outcome in patients with EGFR-mutated non-small cell lung cancer (NSCLC). (2017) (1)
- Clinical benefit of cabazitaxel plus prednisone in the TROPIC trial in men with metastatic (2011) (1)
- Correction to: Pericardial effusion under nivolumab: case-reports and review of the literature (2019) (1)
- 853PPREDICTION OF RESPONSE OF PRIMARY TUMORS TO NEOADJUVANT SUNITINIB USING PERFUSION (DCE) COMPUTED TOMOGRAPHY (CT) IN METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS (PREINSUT TRIAL). (2014) (1)
- Association of hypertension and proteinuria with overall survival in solid-tumor patients treated with anti-VEGF drugs in the MARS study. (2014) (1)
- Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC). (2015) (1)
- 2554 Clinical outcome of initially metastatic hormone sensitive prostate cancer (HSPC) in real life population from a single center: Comparison with initially metastatic HSPC patients included in the GETUG-AFU 15 trial (2015) (1)
- Analysis of PFS2 by subsequent therapy in KEYNOTE-361: Pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as 1L therapy for advanced urothelial carcinoma (UC). (2021) (1)
- EFFICACY AND SAFETY OF IMMUNE CHECKPOINT INHIBITORS (ICIS) FOR TREATMENT OF ADVANCED SOLID TUMORS IN OCTOGENARIAN PATIENTS (2019) (1)
- Validation of a deep learning segmentation algorithm to quantify the skeletal muscle index and sarcopenia in metastatic renal carcinoma (2022) (1)
- Neutropenia, neutrophilia, and neutrophil–lymphocyte ratio as prognostic markers in patients with metastatic castration-resistant prostate cancer (2022) (1)
- [Experimental program personalized care in patients with head and neck cancer]. (2014) (1)
- Overall survival (OS) and efficacy results of second-line treatment in patients (pts) with metastatic clear cell renal cell carcinoma (mRCC) treated in the randomized phase II BIONIKK trial. (2023) (1)
- Everolimus and sunitinib as first- and second-line treatments of patients with metastatic papillary renal cell carcinoma (pRCC): A retrospective study of the GETUG (Groupe Français d’Etude des Tumeurs Uro-Génitales). (2016) (1)
- 861 Impact of prior endocrine therapy on radiographic progression-free survival (rPFS) in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: Results from COU-AA-302 (2014) (1)
- Efficacy and safety of pazopanib in patients with advanced and/or metastatic renal cell carcinoma (mRCC) after previous checkpoint inhibitor treatment (2018) (1)
- Retrospective evaluation of tyrosine kinase inhibitor (TKI)-everolimus (eve) and/or TKI-eve-TKI sequences in metastatic renal cell carcinoma (mRCC): A French survey—The sector study. (2014) (1)
- 7051 POSTER Bicalutamide in Combination With Vandetanib or Placebo in Patients With Castration-refractory Metastatic Prostate Cancer Without Any Clinical Symptom Related to Disease Progression – a Randomized, Double-blind Phase II Trial (2011) (1)
- FIRSTANA: Health-related quality of life (HRQL) and post-hoc analyses for the phase III study assessing cabazitaxel (C) vs docetaxel (D) in chemotherapy-naïve patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (2016) (1)
- Rechallenge of nivolumab in metastatic renal cell carcinoma, an ambispective multicenter study (RENIVO). (2021) (1)
- Effect of addition of docetaxel (D) to hormonal therapy (HT) versus HT alone on quality of life: Results from a phase III study in non-metastatic high-risk prostate cancer (PC) patients (pts) with a rising PSA status. (2013) (1)
- Interest of CHOI and modified CHOI criterion for evaluation of metastatic renal cell carcinomas (mRCC) patients treated with Everolimus (2011) (1)
- Overview and mechanism of action of mTOR inhibitors (2011) (1)
- Expression of EPHRIN-A1, SCINDERIN and MHC class I molecules in head and neck cancers and relationship with the prognostic value of intratumoral CD8+T cells (2013) (1)
- Cancer bronchique, la gestion des situations critiques (2014) (1)
- Association of clinical progression at initiation of a life-extending therapy (LET) in metastatic castration-resistant prostate cancer (mCRPC) with poor prognosis: Results of the CATS database. (2018) (1)
- Glycolytic profile in normal brain tissue and gliomas determined by a micro-method analysis. (1996) (1)
- Post Hoc Health‐Related Quality of Life Analysis According to Response Among Patients with Prostate Cancer in the PROSELICA and FIRSTANA Studies (2021) (1)
- 1451MO In-situ immune markers predict nivolumab (N) +/-ipilimumab (I) efficacy in frontline metastatic clear cell renal cell carcinoma (mccRCC): Key ancillary analyses from the BIONIKK randomized trial (2022) (1)
- [Bladder cancer: realities and perspectives]. (2003) (1)
- Results of a phase II study of carboplatin and etoposide in patients with progressive metastatic castration refractory prostate cancer (mCRPC) and neuro-endocrine differentiation. (2016) (1)
- Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort (2019) (0)
- 292PRADIOLOGICAL-HISTOLOGICAL SIZE CORRELATION IN TRIPLE-NEGATIVE BREAST CANCER (TNBC). (2014) (0)
- 1549PHYPERTENSION, PROTEINURIA AND OVERALL SURVIVAL IN ELDERLY CANCER PATIENTS TREATED WITH BEVACIZUMAB. (2014) (0)
- Carcinomas of the Kidney in Human Clear Cell OGG 1 Alterations of the DNA Repair Gene Updated (2000) (0)
- Docetaxel (DOC) versus new androgen receptor-targeted agent (ART) in metastatic castrate-resistant prostate cancer (mCRPC) patients (pts) having received abiraterone (ABI) or enzalutamide (ENZA) as first-line (L1). (2020) (0)
- 1237 POSTER High incidence of renal insufficiency in ovarian cancer patients (2007) (0)
- Association of Rs1139971, a KAI1 polymorphism, with bone metastasis progression in prostate cancer and ganglionnary metastasis. (2013) (0)
- 1610 Renal function in patients receiving chemotherapy: Impact on survival (2015) (0)
- 1165PImmune checkpoint inhibitors following targeted therapies in MITF family translocation renal cell carcinomas (2017) (0)
- Supportive care in cancer organization in France: State of the art. (2012) (0)
- Is it useful to combine taxanes with targeted agents in mCRPC patients—have we hit the target in this phase II study with docetaxel and curcumin allowing going for a phase III study? (2016) (0)
- 1541PA NETWORK MONITORING PROGRAM TO IMPROVE SAFETY AND MANAGEMENT IN AMBULATORY CHEMOTHERAPY UNIT. (2014) (0)
- 864 Intravenous (IV) vinorelbine (VRL) plus hormone therapy (HT) versus hormone therapy alone in hormone-refractory prostate cancer (HRPC). Final report of a randomised phase III study (2003) (0)
- 1422P Validation of the prognostic value of the early modeled longitudinal PSA kinetics (KELIM and KPROD) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with taxanes in FIRSTANA (2022) (0)
- Optimal molecular selection to benefit from nivolumab-ipilimumab in clear-cell renal cell carcinoma. (2022) (0)
- 7167 POSTER Prognostic Factors for Overall Survival (OS) of Patients (pts) With Locally Advanced (LA) or Metastatic (m) Urothelial Carcinomas (UC) Following Platinum-based Combination Chemotherapy (CT) at Georges Pompidou Hospital (GPH) Between 2001 and 2009 (2011) (0)
- Association of grade ≥3 neutropenia (NP) with outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel. (2018) (0)
- Both Healthy and Cancer Donors by Pre-Existing Naive and Memory Cells in CD4 T Cell Epitopes Differently Recognized The Tumor Antigen Cyclin B1 Hosts Multiple (2015) (0)
- Docetaxel: time to reassess combination strategies. (2013) (0)
- Optimal sequence strategy with nivolumab and targeted therapy in patients with metastatic renal cell carcinoma (mRCC). (2020) (0)
- A model for predicting overall survival in men with metastatic castrate-resistant prostate cancer (CRPC) for whom first-line chemotherapy failed. (2013) (0)
- Epidemiology and CKD - 2 (2009) (0)
- Efficacy of cabozantinib vs everolimus in advanced renal cell carcinoma with bone metastases: results from the phase 3 METEOR study (2017) (0)
- Clinical response and pharmacodynamic assessment of INVAC-1, a DNA plasmid encoding an inactive form of human telomerase reverse transcriptase (hTERT), on immune responses, immune tolerability, tumor burden and circulating tumor DNA (ctDNA) in patients with advanced solid tumors. (2018) (0)
- Pre-emptive monitoring of scheduled chemotherapy reduced toxicity without diminishing efficacy in patients (pts) over age75 with gynecologic (GC) or lung cancer (LC) treated with paclitaxel and carboplatin (PC). (2011) (0)
- Final results of a phase I study evaluating INVAC-1, a novel DNA vaccine expressing an inactive form of human telomerase reverse transcriptase (hTERT) in patients with advanced solid tumors. (2019) (0)
- 712P Primary tumour response in patients treated with nivolumab for metastatic renal cell carcinoma (mRCC): Results of the GETUG-AFU 26 NIVOREN trial (2020) (0)
- Bone markers in prostate cancer (PC) patients: Biologic criteria to identify patients at risk of developing distant metastases. (2009) (0)
- Renal function evolution in cancer patients. Results of the IRMA-2 study. (2009) (0)
- 7134 POSTER Updated Safety and Efficacy Results for Sunitinib From a Global, Expanded-Access Trial in Metastatic Renal Cell Carcinoma (mRCC) (2011) (0)
- First-line pembrolizumab in advanced urothelial carcinoma: Clinical parameters associated with efficacy in the phase 2 KEYNOTE-052 and phase 3 KEYNOTE-361 trials. (2022) (0)
- 221P Patient-reported sexual and urinary function in nonmetastatic castration-resistant prostate cancer (nmCRPC) when treated with apalutamide (APA) vs placebo (PBO) and ongoing androgen deprivation therapy (ADT) in SPARTAN (2020) (0)
- 7016 POSTER Second Line Chemotherapy After Docetaxel Among Symptomatic Castration-Resistant Prostate Cancer (CPRC) Patients – GETUG-P02 Randomized Phase II Trial (2011) (0)
- CMR 2007: 2.03: Can clinical DCE-CT using small molecular iodinated contrast agent detect and quantify the effect of anti-angiogenic drugs on metastatic renal cell carcinoma? (2007) (0)
- 1480P Baseline levels of proinflammatory cytokines according to body mass index (BMI) and BMI impact on clinical outcomes in metastatic renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (NIVO) within the NIVOREN trial (2022) (0)
- [Efficacy of weekly epoetin Beta in the treatment of chemotherapy-induced anemia in solid tumors]. (2009) (0)
- Combination of prostate-specific antigen (PSA) exposure and Gleason score as prognostic factors for prostate cancer (PC) patients (2005) (0)
- 1165P Immune checkpoint inhibitors following targeted therapies in MITF family translocation renal cell carcinomas (2017) (0)
- Supportive care. (1998) (0)
- 1542PDAnticipative approach to improve safety: An innovative daily hospital organisation (2017) (0)
- Modelling relapse in patients with high-risk localised prostate cancer treated randomly in the GETUG 12 phase III trial reveals two populations of relapsing patients (2016) (0)
- Is the natural history of prostate cancer different according to serum neuroendocrine profile (2007) (0)
- 1302 Outcome of elderly patients suffering from solid tumor and admitted to Intensive Care Unit (ICU) (2015) (0)
- Outcomes of systemic therapy in relapsed renal cell carcinoma (RCC) treated with adjuvant sunitinib (AS). (2020) (0)
- Prognostic value of response according to tumour growth rate in a phase I trial on vaccine therapy. (2018) (0)
- Acknowledgement of Reviewers (2004) (0)
- In-patient supportive care unit in oncology: A 3-year assessment (2011-2013). (2014) (0)
- 251PPROGNOSTIC VALUE OF PRE-TREATMENT NEUTROPHIL TO LYMPHOCYTE RATIO IN PATIENTS (PTS) WITH METASTATIC SOLID TUMORS: RESULTS OF AN OBSERVATIONAL COHORT FROM A SINGLE FRENCH CENTER. (2014) (0)
- 104 Overall survival with cabazitaxel is strongly related to PSA response: Results of a retrospective registry in metastatic castration resistant prostate cancer (mCRPC) (2013) (0)
- Circulating Biomarkers in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus in the Pre-nephrectomy Setting. (2022) (0)
- Descriptive analysis of bisphosphonates use in patients with cancer and bone metastasis (2006) (0)
- High glycolosis despite the loss of hexokinase transcription unit in chromosome-10 monosomic human gliomas (1996) (0)
- 1568 Deleterious joint effect of fatigue and anemia in cancer patients treated with chemotherapy (2015) (0)
- Outcomes of systemic targeted therapy in recurrent renal cell carcinoma treated with adjuvant sunitinib (2021) (0)
- Impact of erythropoietin treatment on cognitive status in anaemic patients under chemotherapy: A prospective analysis (2008) (0)
- Abstract P5-17-04: Management of Antiangiogenics' Renovascular Safety in breast cancer. Subgroup and intermediate results of the MARS Study. (2012) (0)
- Bladder Sequential Sorafenib and Sunitinib for Renal Cell Carcinoma (0)
- PSA response and early PSA progression evaluated in patients randomized in a phase III trial comparing androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in hormone-naive metastatic prostate cancer (GETUG-AFU 15/0403). (2011) (0)
- 544P Feasibility of two different first-line carboplatin plus paclitaxel regimens in elderly women with ovarian cancer: A retrospective study (2022) (0)
- 430 Dose finding of inecalcitol, a new VDR agonist, in combination with docetaxel–prednisone regimen for castrate-resistant prostate cancer (HRPC) patients (pts) (2010) (0)
- 63 POSTER Response of papillary cell carcinoma to antiangiogenics: a retrospective analysis (2008) (0)
- POSC134 Cost-Effectiveness Analysis of Innovative Therapy for Patients with Newly Diagnosed Hormone-Sensitive Metastatic Prostate Cancer (2022) (0)
- Optimum timing of gefitinib therapy in metastatic non-small cell lung cancer (NSCLC) patients (2005) (0)
- 634P Prognostic value of the modeled PSA kinetic parameter (KELIM) in prostate cancer patients with rising PSA after primary local therapy treated in a prospective phase III trial with ADT +/- docetaxel (2021) (0)
- Real-world evidence of patients with metastatic castration-resistant prostate cancer treated with cabazitaxel: comparison with the randomized clinical study CARD (2022) (0)
- 248 SUNITINIB IN PATIENTS (PTS) WITH OR WITHOUT PRIOR NEPHRECTOMY IN AN EXPANDED-ACCESS STUDY OF METASTATIC RENAL CELL CARCINOMA (MRCC) (2009) (0)
- A rapidly progressing leiomyosarcoma expressing drug-resistance markers failed to respond to cyclosporin A-associated chemotherapy. (1994) (0)
- Relationship between kalemia and ICU admission or death in hospitalized COVID-19 patients: A monocentric cohort study (2021) (0)
- Mitochondria structural modifications, mitochondria‐bound hexokinase, glycolysis and oxidative phosphorylation in human gliomas (1995) (0)
- [Severe hemorrhagic complications during treatment with low molecular weight heparin. Apropos of 2 cases]. (1997) (0)
- Renovascular safety of sunitinib in prostate cancer: The prognostic value of hypertension and proteinuria. (2015) (0)
- 1582 Longitudinal study on the impact of patient-reported fatigue on survival in metastatic cancer patients treated with chemotherapy (2015) (0)
- Renal function evolution in cancer patients. Results of the IRMA-2 study (2009) (0)
- IMvigor010: Updated analysis of Overall Survival (OS) by circulating tumour DNA (ctDNA) status in patients with post-operative Muscle-Invasive Urothelial Carcinoma (MIUC) treated with atezolizumab (2022) (0)
- 2645 Drug-drug interactions with sunitinib at treatment initiation in kidney cancer: Need for communication and multidisciplinary care with GPs (2015) (0)
- [In the treatment of mCRPC, the question is to administer the right molecule to the right patient, at the right time]. (2013) (0)
- 645P Prediction of BRCA2 mutations in prostate cancer patients according early onset, metastatic phenotypes or family history of breast/ovary cancer (2020) (0)
- Cabazitaxel multiple rechallenge in metastatic castration-resistant prostate cancer: A therapeutic option to increase overall survival? (2021) (0)
- [Lung cancer, how to deal with critical situations?]. (2014) (0)
- 97 EVEROLIMUS (EVE) IN RECORD-1 ELDERLY PATIENTS (PTS) WITH METASTATIC RENAL CELL CARCINOMA (MRCC) AND MANAGEMENT OF RELATED ADVERSE EVENTS (AES) (2010) (0)
- EP222 Indocyanine green for sentinel lymph node detection in early breast cancer: prospective evaluation of detection rate and toxicity (2019) (0)
- [Case report of kidney cancer from JOUM 2010]. (2011) (0)
- Molecular characterization of heterogeneity in circulating tumor cells (CTCs) and tumor samples of metastatic castration-resistant prostate cancer (mCRPC) patients: The multicenter PETRUS program. (2015) (0)
- Selected Abstracts presented at the XIII Symposium of the International Society of Oncology Pharmacy Practitioners, 9–11 May 2012, Melbourne, Australia (2012) (0)
- [Cancers of the kidney: multiple drug resistance]. (1993) (0)
- Hypertension and impaired renal function as biomarkers of efficacy of bevacizumab (bev) in ovarian cancer: A retrospective study. (2015) (0)
- Prognosis impact of serous metastases (SMs) in clear cell renal cell carcinoma patients in the GETUG-AFU-26 NIVOREN phase II trial. (2021) (0)
- [Resistance to chemotherapy in cancers of the kidney and therapeutic perspectives]. (1995) (0)
- 71 INVITED Defining Response – Oncological Imaging's New Challenge (2011) (0)
- Prognostic value of various summary measures of prostate-specific antigen (PSA) kinetics for overall survival (OS) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) who failed first-line chemotherapy (TROPIC trial). (2013) (0)
- Efficacy and safety of sorafenib in patients with advanced clear-cell renal cell carcinoma (RCC) with diabetes: Results from the phase III TARGET study. (2009) (0)
- Future treatment options in metastatic clear cell renal cell carcinoma. (2022) (0)
- Patterns of treatment (trx) and safety of angiogenesis inhibitors in patients (pts) with advanced renal cell carcinoma (RCC) in France. (2011) (0)
- Supportive care organization: Patients and oncologist national survey comparison. (2014) (0)
- Taxanes Versus Androgen Receptor Therapy as Second-Line Treatment for Castrate-Resistant Metastatic Prostate Cancer After First-Line Androgen Receptor Therapy. (2023) (0)
- Platelet microparticles (PMP): A predictive factor of overall survival in hormone-refractory prostate cancer (HRPC) patients treated by chemotherapy. (2006) (0)
- Post-hoc analysis of long-term outcomes in patients with CR, PR, or SD to pembrolizumab (pembro) or platinum-based chemotherapy (chemo) as 1L therapy for advanced urothelial carcinoma (UC) in KEYNOTE-361. (2021) (0)
- Activity of docetaxel (D) and new generation hormonotherapies (NGH) in patients with metastatic castrate-resistant prostate cancer (mCRPC) following front line cabazitaxel (C). (2015) (0)
- Anemia, renal disease, and chemotherapy in the IRMA study (2008) (0)
- 2612 Prognostic value of baseline Neutrophil to Lymphocyte Ratio (NLR) in metastatic Urothelial Carcinomas (mUC) patients (pts) treated with first-line chemotherapy (CT): A large retrospective multicenter study (2015) (0)
- Early placenta insuline-like peptide (pro-EPIL): A novel biomarker in advanced and metastatic non-small cell lung cancer (NSCLC) patients treated by chemotherapy. (2006) (0)
- Real-world data of cabozantinib in patients with VEGF-refractory metastatic renal cell carcinoma (mRCC): Results from the French Early Access Program (CABOREAL). (2020) (0)
- 25 Randomized phase II study of cisplatine gemcitabine (PG) versus mitomycine ifosfamide cisplatine (MIP) in non-small cell lung cancer (NSCLC): an interim analysis (2003) (0)
- 139O SERUM HER-2/NEU DECLINE PREDICTS IMPROVED RESPONSE TO TRASTUZUMAB-BASED THERAPY (2006) (0)
- [Treatment of metastatic prostate cancer: what recent progress?] (2018) (0)
- [Castration modalities in prostate cancer: Are they all equal?]. (2016) (0)
- [Prostate cancer and chemotherapy: standards care and perspectives]. (2012) (0)
- Safety and efficacy of immunotherapy according to the age threshold of 80 years. (2023) (0)
- Pain progression at initiation of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) is associated with a poor prognosis: a post-hoc analysis of PROSELICA. (2020) (0)
- Feasibility of an adapted schedule of carboplatin + paclitaxel in elderly women with Ovarian Cancer: a retrospective cohort (2021) (0)
- 673P Cabozantinib-nivolumab (CN) vs. nivolumab-cabozantinib (NC) in patients (pts) with metastatic clear cell renal cell carcinoma (mRCC) following one prior VEGFR tyrosine kinase inhibitor (TKI): The CABIR multicentric matching-adjusted study (2021) (0)
- Correlation of longitudinal target-lesions size with progression-free (PFS) and overall-survival (OS) in 2nd line metastatic renal cell carcinoma: a retrospective analysis of AXIS trial (2016) (0)
- An enhancer demethylator phenotype converged to immune dysfunction and resistance to immune checkpoint inhibitors in clear-cell renal cell carcinomas. (2022) (0)
- Effect of neoadjuvant alternating taxane- and anthracycline-based dose-dense regimen for operable breast cancer on prognosis in triple-negative tumors with a complete histological response. (2010) (0)
- Abstract LB-497: Primary tumor localization determines the metastatic immune profile (2012) (0)
- 1503 Impact of pain on survival in metastatic cancer patients treated with chemotherapy: A prospective longitudinal study of patient-reported severity (2015) (0)
- 2538 Response to cabazitaxel in patients with metastatic castrationresistant prostate cancer (mCRPC) poorly responding to docetaxel (2015) (0)
- Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France (2015) (0)
- Gemcitabine plus platinum-based chemotherapy in combination with bevacizumab for kidney metastatic collecting duct and medullary carcinomas: Results of a prospective phase II trial (BEVABEL-GETUG/AFU24). (2023) (0)
- Targeting of glucose metabolism gene in advanced gliomas (1998) (0)
- Association du rs1139971, polymorphisme du gène KAI1, à la progression métastatique osseuse dans le cancer de prostate mais pas à la progression métastatique ganglionnaire (2013) (0)
- Erratum to 'Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration-resistant prostate cancer: The CATS international database' [European Journal of Cancer, Volume 125 (January 2020) Pages 153-163]. (2020) (0)
- Feasibility of an adapted schedule of carboplatin plus paclitaxel in elderly women with advanced ovarian cancer: A retrospective cohort. (2021) (0)
- What is the benfit of mTOR inhibitors (mTORi) rechallenge in metastatic renal clear cell carcinoma (mRCC) patients (pts) initially treated with TKI? (2012) (0)
- Assessment of frozen glove use in the prevention of docetaxel induced onycholysis and cutaneous reaction. Results of a multicenter case-control study. (2004) (0)
- Impact of non-proportionality of hazards on time-to-event endpoints with nivolumab: Re-analysis of melanoma and NSLCC pivotal trials (2016) (0)
- 801PEffect of sequence on outcome of prostate cancer patients: retrospective study of a French cohort (2017) (0)
- [Chemotherapy for prostate cancer]. (2008) (0)
- An exploratory determination of new bone markers in natural history of prostate cancer (PC) patients. (2010) (0)
- 771PANALYSIS OF OVERALL SURVIVAL (OS) FOR PATIENTS (PTS) WITH DIFFERENT PROGNOSTIC RISK FACTORS TREATED WITH CABAZITAXEL AND PREDNISONE (CBZ + P) AFTER DOCETAXEL (D) IN THE TROPIC TRIAL. (2014) (0)
- How molecularly similar are primary and metastatic tissues in renal cell carcinoma? - Authors' reply. (2022) (0)
- 1400 POSTER DISCUSSION Interest of CHOI and Modified CHOI Criterion for Evaluation of Metastatic Renal Cell Carcinomas (mRCC) Patients Treated With Everolimus (2011) (0)
- Corrected area under prostate-specific antigen (PSA) curve and PSA half-time dynamics during chemotherapy. A new prognostic classification for hormone-refractory prostate cancer (HRPC) patients (2005) (0)
- 831PSKELETAL MUSCLE INDEX (SMI) IS A PROGNOSTIC FACTOR IN METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS TREATED WITH EVEROLIMUS: A RETROSPECTIVE STUDY. (2014) (0)
- Corrigendum to "Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database" [Eur J Canc 125, (January 2020) 153-163]. (2020) (0)
- Metastatic clear cell renal cell carcinoma: Proangiogenic gene expression and outcome on sunitinib. (2017) (0)
- Editorial comment on: combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. (2008) (0)
- [Oncology and other specialities Centre of the Georges-Pompidou European hospital: a model of unifying pneumology and oncology network]. (2014) (0)
- Supportive care organization in France: State of the art. (2011) (0)
- 142Plongitudinal exploratory analysis of prior- surgery everolimus circulating and clinical biomarkers in locally advanced and metastatic renal cell carcinoma patients (RCC) (2017) (0)
- Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma (2017) (0)
- 1510PANEMIA AS AN EXPLANATORY FACTOR FOR FATIGUE IN PATIENTS TREATED WITH CHEMOTHERAPY. (2014) (0)
- Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study. (2023) (0)
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma. (2023) (0)
- 584P Health-related quality of life (HRQoL) in ACIS: A phase III trial of apalutamide with abiraterone acetate and prednisone (APA + AAP) vs AAP in metastatic castration-resistant prostate cancer (mCRPC) (2021) (0)
- 1382PSUPPORTIVE CANCER CARE IN-PATIENT UNIT: A THREE YEARS EXPERIENCE. (2014) (0)
- The immunoscore in patients with urothelial carcinoma treated with neoadjuvant chemotherapy: Clinical significance for pathological response and survival (2019) (0)
- Abstract A085: Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary clear cell renal cell cancer (2016) (0)
- 7060 POSTER Assessment of Angiogenic Factors and Hematopoietic Stem Cells and Their Relevance as Prognostic Factors for Overall Survival (OS) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients (pts): a Prospective Study (2011) (0)
- Biomarkers of Everolimus Efficacy in Patients with Metastatic Renal Cell Carcinoma (MRCC): Analysis of the Phase III Record-1 Trial (2012) (0)
- A phase II-III, multicenter, randomized, open study evaluating the feasibility and efficacy of a supervised home-based standard physical exercise program for metastatic cancer patients receiving oral targeted therapy: The UNICANCER SdS 01 QUALIOR study (ID-RCB: 2015-A01922-47). (2017) (0)
- Cabazitaxel (CBZ) Shows Superior Antitumor Efficacy Over Docetaxel in a Hormone-Resistant Prostate Tumor Xenograft Model (HID28) (2012) (0)
- Association of adrenal metastases with outcomes in patients with metastatic clear cell renal cell carcinoma (mccRCC) treated with nivolumab in the GETUG-AFU-26 NIVOREN phase II trial. (2022) (0)
- Adaptation of chemotherapy to the decline tumor markers in patients with poor prognosis nonseminomatous germ cell tumors:Real-world French experience. (2021) (0)
- Hypertension, proteinuria, and overall survival in elderly cancer patients treated with bevacizumab. (2014) (0)
- 1762P MERINOS: Metastatic non muscle invasive urothelial carcinoma - An observational study (2022) (0)
- Hormone therapy modality influences the delay and frequency of hormone escape of prostate cancer in a xenograft human model (2007) (0)
- 670P Cabozantinib associated with concomitant radiotherapy or a bone targeted agent (multimodal approach, results from the CABOREAL study post-hoc analysis) (2021) (0)
- Corrected area under serum PSA curve as a predictor of survival after chemotherapy for hormone-refractory prostate cancer (HRPC) patients (2004) (0)
- Phase III AXIS trial for second-line metastatic renal cell carcinoma (mRCC): Effect of prior first-line treatment duration and axitinib dose titration on axitinib efficacy. (2012) (0)
- 7061 POSTER Assessment of Bone Remodeling Markers and Their Relevance as Prognostic Factors for Overall Survival (OS) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients (Pts) Treated With Sunitinib (S) After Docetaxel Failure – a Prospective Study (2011) (0)
- Anticipative monitoring to improve chemotherapy induced nausea. (2017) (0)
- Renal insufficiency in lung cancer patients. Subgroup analysis of the IRMA study: P1-263 (2007) (0)
- Mechanisms of resistance to docetaxel and therapeutic strategy (2012) (0)
- 1376PSUPPORTIVE CARE ORGANIZATION COMPARED BETWEEN PATIENTS AND ONCOLOGIST NATIONAL SURVEY. (2014) (0)
- Correlation of regulatory T-cell levels and overall survival in metastatic renal cancer patients treated with sunitinib-based therapy. (2010) (0)
- [Dose individualization for carboplatin in cancer chemotherapy]. (1997) (0)
- Analysis of two poor prognosis subgroups in ACIS evaluating apalutamide + abiraterone acetate plus prednisone (APA + AAP) versus placebo (PBO) + AAP in metastatic castration-resistant prostate cancer (mCRPC). (2021) (0)
- CYCLONE 1: A phase 2 study of abemaciclib in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a novel hormonal agent and taxane-based chemotherapy. (2021) (0)
- [Role of supportive care in lung cancer]. (2008) (0)
- Exposure toxicity and response relationship of cabozantinib (CABO) in patients with metastatic renal cell carcinoma (mRCC). (2023) (0)
- Epidemiology and CKD - 3 (2009) (0)
- Apalutamide compared with darolutamide for the treatment of non-metastatic castration resistant prostate cancer: efficacy and tolerability in a matching-adjusted indirect comparison (2022) (0)
- Fatigue (F) and Anemia Scores for Overall Survival (OS) Prognosis (2012) (0)
- Administration of neoadjuvant chemotherapy for muscle-invasive bladder cancer in real life: Are urologists still too cautious? (2021) (0)
- 795PA PROGNOSTIC MODEL FOR PREDICTING RADIOGRAPHIC PROGRESSION- FREE SURVIVAL (RPFS) IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER MEN TREATED WITH SECOND-LINE CHEMOTHERAPY. (2014) (0)
- Renovascular Safety of Sunitinib in Renal Cell Carcinoma: The Prognostic Value of Hypertension and Proteinuria (2017) (0)
- A prognostic model for predicting overall survival in metastatic castrate-resistant prostate cancer (mCRPC) men treated with second-line chemotherapy. (2013) (0)
- Renal Insufficiency in Breast Cancer Patients: High Prevalence and Reduced Survival. (2009) (0)
- Phase II combination of gefitinib and docetaxel for advanced or metastatic non-small cell lung cancer: clinical results and biological monitoring (2006) (0)
- Corrigendum to "Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study" [Eur Urol 83 (2023) 15-26]. (2022) (0)
- Abstract A27: Efficacy of estramustine + docetaxel in docetaxel‐resistant human prostate cancer xenograft: a preclinical model of docetaxel resistance reversion (2009) (0)
- Validation of the Correlation Between Single Nucleotide Polymorphism rs307826 in VEGFR3 and Outcome in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Sunitinib (2020) (0)
- Pharmacokinetic (PK) analysis of two dosing schedules of the angiokinase inhibitor BIBF 1120 in patients with hormone- refractory prostate cancer (HRPC) who progressed after docetaxel treatment (2008) (0)
- 4005 ORAL An open label randomized Phase II study of oral triple angiokinase inhibitor BIBF 1120 in Hormone Refractory Prostate Cancer (HRPC) patients who progressed after docetaxel (2007) (0)
- PROCHE: A program to improve the organization of a medical oncology outpatient unit. (2010) (0)
- Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort (2019) (0)
- Development and validation of prognostic models in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib: A Greek-French collaboration. (2012) (0)
- 311 A pharmacogenomic scoring system predicting median time-to-progression on sunitinib as first line treatment in patients with metastatic renal cell carcinoma (2012) (0)
- 866PIMPACT OF PLATINUM AGENT [CISPLATIN (CIS) OR CARBOPLATIN (CA)] IN FIRST-LINE CHEMOTHERAPY (CT) ON OVERALL SURVIVAL IN METASTATIC UROTHELIAL CARCINOMA (MUC) PATIENTS (PTS): A RETROSPECTIVE STUDY. (2014) (0)
- Toxicity symptom reporting by patients and clinicians during phase III trial comparing androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in hormone-naïve metastatic prostate cancer (GETUG-AFU 15/0403). (2010) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Stephane Marie Oudard?
Stephane Marie Oudard is affiliated with the following schools:
